<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2803245119
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ADVAGRAF 0.5MG PROLONGED RELEASE CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TACROLIMUS
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        347.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Astellas Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Astellas Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Advagraf contains the active substance tacrolimus. It is an immunosuppressant. Following your organ transplant (liver, kidney), your body&rsquo;s immune system will try to reject the new organ. Advagraf is used to control your body&rsquo;s immune response, enabling your body to accept the transplanted organ.</p><p>You may also be given Advagraf for an ongoing rejection of your transplanted liver, kidney, heart or other organ when any previous treatment you were taking was unable to control this immune response after your transplantation.</p><p>Advagraf is used in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Advagraf </strong></p><ul><li>If you are allergic (hypersensitive) to tacrolimus or any of the other ingredients of Advagraf (see section 6).</li><li>If you are allergic to sirolimus or to any macrolide-antibiotic (e.g. erythromycin, clarithromycin, josamycin).</li></ul><p><strong>Warnings and Precautions</strong><br />Prograf and Advagraf both contain the active substance, tacrolimus. However, Advagraf is taken once daily, whereas Prograf is taken twice daily. This is because Advagraf capsules allow for a prolonged release (more slow release over a longer period) of tacrolimus. Advagraf and Prograf are not interchangeable.</p><p>Talk to your doctor or pharmacist before taking Advagraf:</p><ul><li>If you are taking any medicines mentioned below under &quot;Other medicines and Advagraf&quot;.</li><li>If you have or have had liver problems.</li><li>If you have diarrhoea for more than one day.</li><li>If you feel strong abdominal pain accompanied or not with other symptoms, such as chills, fever, nausea or vomiting.</li><li>If you have an alteration of the electrical activity of your heart called &quot;QT prolongation&quot;.</li><li>If you have or have had damage to the smallest blood vessels, known as thrombotic microangiopathy/thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome. Tell your doctor if you develop fever, bruising under the skin (which may appear as red dots), unexplained tiredness, confusion, yellowing of the skin or eyes, reduced urine output, vision loss and seizures (see section 4). When tacrolimus is taken together with sirolimus or everolimus, the risk of developing these symptoms may increase.</li></ul><p>Please avoid taking any herbal remedies, e.g. St. John&rsquo;s wort (Hypericum perforatum) or any other herbal products as this may affect the effectiveness and the dose of Advagraf that you need to receive.</p><p>If in doubt please consult your doctor prior to taking any herbal products or remedies.</p><p>Your doctor may need to adjust your dose of Advagraf.</p><p>You should keep in regular contact with your doctor. From time to time, your doctor may need to do blood, urine, heart, eye tests, to set the right dose of Advagraf.</p><p>You should limit your exposure to the sun and UV (ultraviolet) light whilst taking Advagraf. This is because immunosuppressants could increase the risk of skin cancer. Wear appropriate protective clothing and use a sunscreen with a high sun protection factor.</p><p><strong>Precaution for handling</strong><br />Direct contact with any part of your body like your skin or eyes, or breathing in of injection solutions, powder or granules contained in tacrolimus products should be avoided during preparation. If such contact occurs, wash the skin and eyes.</p><p><strong>Children and adolescents</strong><br />The use of Advagraf is not recommended in children and adolescents under 18 years.</p><p><strong>&nbsp;Other medicines and Advagraf</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal preparations.</p><p>It is not recommended that Advagraf is taken with ciclosporin (another medicine used for the prevention of transplant organ rejection).</p><p>If you need to attend a doctor other than your transplant specialist, tell the doctor that you are taking tacrolimus. Your doctor may need to consult your transplant specialist if you should use another medicine that could increase or decrease your tacrolimus blood level.</p><p>Advagraf blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking Advagraf, which may require interruption, an increase or a decrease in Advagraf dose.</p><p>Some patients have experienced increases in tacrolimus blood levels while taking other medicines. This could lead to serious side effects, such as kidney problems, nervous system problems, and heart rhythm disturbances (see section 4).</p><p>An effect on the Advagraf blood levels may occur very soon after starting the use of another medicine, therefore frequent continued monitoring of your Advagraf blood level may be needed within the first few days of starting another medicine and frequently while treatment with the other medicine continues. Some other medicines may cause tacrolimus blood levels to decrease, which could increase the risk of rejecting the transplanted organ. In particular, you should tell your doctor if you are taking or have recently taken medicines like:</p><ul><li>Antifungal medicines and antibiotics, particularly so-called macrolide antibiotics, used to treat infections e.g. ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, clotrimazole, isavuconazole, miconazole, caspofungin telithromycin, erythromycin, clarithromycin, josamycin, azithromycin, rifampicin, rifabutin, isoniazid and flucloxacillin.</li><li>letermovir, used to prevent illness caused by CMV (human cytomegalovirus).</li><li>HIV protease inhibitors (e.g ritonavir, nelfinavir, saquinavir), the booster medicine cobicistat, and combination tablets, or HIV non‐nucleoside reverse transcriptase inhibitors (efavirenz, etravirine, nevirapine) used to treat HIV infection.</li><li>HCV protease inhibitors (e.g. telaprevir, boceprevir, the combination ombitasvir/paritaprevir/ritonavir with or without dasabuvir, elbasvir/grazoprevir, and glecaprevir/pibrentasvir), used to treat hepatitis C infection.</li><li>Nilotinib and imatinib, idelalisib, ceritinib, crizotinib, apalutamide, enzalutamide, or mitotane (used to treat certain cancers).</li><li>Mycophenolic acid used to suppress the immune system to prevent transplant rejection.</li><li>Medicines for stomach ulcer and acid reflux (e.g. omeprazole, lansoprazole or cimetidine).</li><li>Antiemetics, used to treat nausea and vomiting (e.g. metoclopramide).</li><li>Cisapride or the antacid magnesium-aluminium-hydroxide, used to treat heartburn.</li><li>The contraceptive pill or other hormone treatments with ethinylestradiol, hormone treatments with danazol.</li><li>Medicines used to treat high blood pressure or heart problems (e.g. nifedipine, nicardipine, diltiazem and verapamil).</li><li>Anti-arrhythmic drugs (amiodarone) used to control arrhythmia (uneven beating of the heart).</li><li>Medicines known as &ldquo;statins&rdquo; used to treat elevated cholesterol and triglycerides.</li><li>Carbamazepine, phenytoin or phenobarbital used to treat epilepsy.</li><li>Metamizole, used to treat pain and fever.</li><li>The corticosteroids prednisolone and methylprednisolone, belonging to the class of corticosteroids used to treat inflammations or suppress the immune system (e.g. in transplant rejection).</li><li>Nefazodone, used to treat depression.</li><li>Herbal preparations containing St. John&#39;s Wort (Hypericum perforatum) or extracts of Schisandra sphenanthera.</li><li>Cannabidiol (uses amongst others include treatment of seizures).</li></ul><p>Tell your doctor if you are receiving treatment for hepatitis C. The drug treatment for hepatitis C may change your liver function and may affect blood levels of tacrolimus. Tacrolimus blood levels may fall or may increase depending on the medicines prescribed for hepatitis C. Your doctor may need to closely monitor tacrolimus blood levels and make necessary adjustments of Advagraf dose after you start treatment for hepatitis C.</p><p>Tell your doctor if you are taking or need to take ibuprofen (used to treat fever, inflammation and pain), antibiotics (cotrimoxazole, vancomycin, or aminoglycoside antibiotics such as gentamicin), amphotericin B (used to treat fungal infections) or antivirals (used to treat viral infections e.g. acyclovir, ganciclovir, cidofovir, foscarnet). These may worsen kidney or nervous system problems when taken together with Advagraf.</p><p>Tell your doctor if you are taking sirolimus or everolimus. When tacrolimus is taken together with sirolimus or everolimus, the risk of developing thrombotic microangiopathy, thrombotic thrombocytopenic purpura, and haemolytic uraemic syndrome may increase (see section 4).</p><p>Your doctor also needs to know if you are taking potassium supplements or certain diuretics used for heart failure, hypertension and kidney disease, (e.g. amiloride, triamterene, or spironolactone), or the antibiotics trimethoprim or cotrimoxazole that may increase levels of potassium in your blood, non-steroidal anti-inflammatory drugs (NSAIDs, e.g. ibuprofen) used for fever, inflammation and pain, anticoagulants (blood thinners), or oral medicines for diabetes, while you take Advagraf.</p><p>If you need to have any vaccinations, please tell your doctor before.</p><p><strong>Advagraf with food and drink</strong><br />Avoid grapefruit (also as juice) while on treatment with Advagraf, since it can affect its levels in the blood.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are, think you might be or are planning to become pregnant, ask your doctor for advice before using Advagraf.</p><p>Advagraf<strong> </strong>passes into breast milk. Therefore, you should not breast-feed whilst using Advagraf.</p><p><strong>&nbsp;Driving and using machines</strong><br />Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking Advagraf. These effects are more frequent if you also drink alcohol.</p><p><strong>Advagraf </strong><strong>contains lactose monohydrate, sodium and lecithin (soya)</strong><br />Advagraf<strong> </strong>contains lactose monohydrate. Each prolonged-release hard capsule of Advagraf 0.5 mg, 1 mg, 3 mg and 5 mg Prolonged-release Hard Capsules contains 53.64 mg, 107.28 mg, 321.84 mg or 536.4 mg lactose monohydrate; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Advagraf<strong> </strong>contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per prolonged-release hard capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>The printing ink used on Advagraf prolonged-release hard capsules<strong> </strong>contains lecithin (soya). Each prolonged-release hard capsule of Advagraf 0.5 mg, 1 mg, 3 mg and 5 mg Prolonged-release Hard Capsules contains 0.0009 mg, 0.0008 mg, 0.0013 mg or 0.0015 mg lecithin (soya); respectively. If you are allergic to peanut or soya, talk to your doctor to determine whether you should use this medicine.<strong>&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Advagraf<strong> </strong>exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. This medicine should only be prescribed to you by a doctor with experience in the treatment of transplant patients.</p><p>Make sure that you receive the same tacrolimus medicine every time you collect your prescription, unless your transplant specialist has agreed to change to a different tacrolimus medicine. This medicine should be taken once a day. If the appearance of this medicine is not the same as usual, or if dosage instructions have changed, speak to your doctor or pharmacist as soon as possible to make sure that you have the right medicine.</p><p>The starting dose to prevent the rejection of your transplanted organ will be determined by your doctor calculated according to your body weight. Initial daily doses just after transplantation will generally be in the range of 0.10 &ndash; 0.30 mg per kg body weight per day depending on the transplanted organ. When treating rejection, these same doses may be used.</p><p>Your dose depends on your general condition and on which other immunosuppressive medication you are taking.</p><p>Following the initiation of your treatment with Advagraf, frequent blood tests will be taken by your doctor to define the correct dose. Afterwards regular blood tests by your doctor will be required to define the correct dose and to adjust the dose from time to time. Your doctor will usually reduce your Advagraf<strong> </strong>dose once your condition has stabilised. Your doctor will tell you exactly how many capsules to take.</p><p>You will need to take Advagraf<strong> </strong>every day as long as you need immunosuppression to prevent rejection of your transplanted organ. You should keep in regular contact with your doctor.</p><p>Advagraf<strong> </strong>is taken orally once daily in the morning. Take Advagraf<strong> </strong>on an empty stomach or 2 to 3 hours after a meal. Wait at least 1 hour until the next meal. Take the capsules immediately following removal from the blister. The capsules should be swallowed whole<strong> </strong>with a glass of water. Do not swallow the desiccant contained in the foil wrapper.</p><p><strong>If you take more Advagraf<strong> </strong>than you should</strong><br />If you have accidentally taken too much Advagraf, contact your doctor or nearest hospital emergency department immediately.</p><p><strong>If you forget to take Advagraf</strong><br />If you have forgotten to take your Advagraf<strong> </strong>capsules in the morning, take them as soon as possible on the same day. Do not take a double dose the next morning.</p><p><strong>&nbsp;If you stop taking Advagraf</strong><br />Stopping your treatment with Advagraf<strong> </strong>may increase the risk of rejection of your transplanted organ. Do not stop your treatment unless your doctor tells you to do so.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Advagraf<strong> </strong>can cause side effects, although not everybody gets them.</p><p>Advagraf<strong> </strong>reduces your body&rsquo;s defense mechanism (immune system), which will not be as good at fighting infections. Therefore, you may be more prone to infections while you are taking Advagraf.</p><p>Some infections could be serious or fatal and may include infections caused by bacteria, viruses, fungi, parasites, or other infections.</p><p>Tell your doctor immediately if you get signs of an infection including:</p><ul><li>Fever, cough, sore throat, feeling weak or generally unwell.</li><li>Memory loss, trouble thinking, difficulty walking or loss of vision - these may be due to a very rare, serious brain infection, which can be fatal (Progressive Multifocal Leukoencephalopathy or PML).</li></ul><p>Severe effects may occur, including allergic and anaphylactic reactions. Benign and malignant tumours have been reported following Advagraf<strong> </strong>treatment.</p><p><strong><em>Tell your doctor immediately if you have or suspect you may have any of the following serious side effects:</em></strong><br /><strong>Serious common side effects (may affect up to 1 in 10 people):</strong></p><ul><li>Gastrointestinal perforation: strong abdominal pain accompanied or not with other symptoms, such as chills, fever, nausea or vomiting.</li><li>Insufficient function of your transplanted organ.</li><li>Blurred vision.</li></ul><p><strong>Serious uncommon side effects (may affect up to 1 in 100 people):</strong></p><ul><li>Thrombotic microangiopathy (damage to the smallest blood vessels) including haemolytic uraemic syndrome, a condition with the following symptoms: low or no urine output (acute renal failure), extreme tiredness, yellowing of the skin or eyes (jaundice) and abnormal bruising or bleeding and signs of infection.</li></ul><p><strong>Serious rare side effects (may affect up to 1 in 1,000 people):</strong></p><ul><li>Thrombotic Thrombocytopenic Purpura: a condition involving damage to the smallest blood vessels and characterised by fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice), with symptoms of acute renal failure (low or no urine output), vision loss and seizures.</li><li>Toxic epidermal necrolysis: erosion and blistering of skin or mucous membranes, red swollen skin that can detach in large parts of the body.</li><li>Blindness.</li></ul><p><strong>Serious very rare side effects (may affect up to 1 in 10,000 people):</strong></p><ul><li>Stevens-Johnson syndrome: unexplained widespread skin pain, facial swelling, serious illness with blistering of skin, mouth, eyes and genitals, hives, tongue swelling, red or purple skin rash that spreads, skin shedding.</li><li>Torsades de Pointes: change in the heart frequency that can be accompanied or not of symptoms, such as chest pain (angina), faint, vertigo or nausea, palpitations (feeling the heartbeat) and difficulty breathing.</li></ul><p><strong>Serious side effects &ndash; frequency not known (frequency cannot be estimated from the available data):</strong></p><ul><li>Opportunistic infections (bacterial, fungal, viral and protozoal): prolonged diarrhea, fever and sore throat.</li><li>Benign and malignant tumours have been reported following treatment as a result of immunosuppression.</li><li>Cases of pure red cell aplasia (a very severe reduction in red blood cell counts), haemolytic anaemia (decreased number of red blood cells due to abnormal breakdown accompanied with tiredness) and febrile neutropenia (a decrease in the type of white blood cells which fight infection, accompanied by fever) have been reported. It is not known exactly how often these side effects occur. You may have no symptoms or depending on the severity of the condition, you may feel: fatigue, apathy, abnormal paleness of the skin (pallor), shortness of breath, dizziness, headache, chest pain and coldness in hands and feet.</li><li>Cases of agranulocytosis (a severely lowered number of white blood cells accompanied with ulcers in the mouth, fever and infection(s)). You may have no symptoms or you may feel sudden fever, rigors and sore throat.</li><li>Allergic and anaphylactic reactions with the following symptoms: a sudden itchy rash (hives), swelling of hands, feet, ankle, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing) and you may feel you are going to faint.</li><li>Posterior Reversible Encephalopathy Syndrome (PRES): headache, confusion, mood changes, fits, and disturbances of your vision. These could be signs of a disorder known as posterior reversible encephalopathy syndrome, which has been reported in some patients treated with tacrolimus.</li><li>Optic neuropathy (abnormality of the optic nerve): problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or restriction of your field of vision.</li></ul><p><strong><em>The side effects listed below may also occur after receiving Advagraf and could be serious:</em></strong><br /><strong>Very common side effects (may affect more than 1 in 10 people):</strong></p><ul><li>Increased blood sugar, diabetes mellitus, increased potassium in the blood.</li><li>Difficulty in sleeping.</li><li>Trembling, headache.</li><li>Increased blood pressure.</li><li>Liver function tests abnormal.</li><li>Diarrhoea, nausea.</li><li>Kidney problems.</li></ul><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><ul><li>Reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts (seen in blood tests).</li><li>Reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, increased uric acid or lipids in the blood, decreased appetite, increased acidity of the blood, other changes in the blood salts (seen in blood tests).</li><li>Anxiety symptoms, confusion and disorientation, depression, mood changes, nightmare, hallucination, mental disorders.</li><li>Fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders.</li><li>Increased sensitivity to light, eye disorders.</li><li>Ringing sound in your ears.</li><li>Reduced blood flow in the heart vessels, faster heartbeat.</li><li>Bleeding, partial or complete blocking of blood vessels, reduced blood pressure.</li><li>Shortness in breath, changes in the lung tissue, collection of liquid around the lung, inflammation of the pharynx, cough, flu-like symptoms.</li><li>Inflammations or ulcers causing abdominal pain or diarrhoea, bleeding in the stomach, inflammations or ulcers in the mouth, collection of fluid in the belly, vomiting, abdominal pains, indigestion, constipation, flatulence, bloating, loose stools, stomach problems.</li><li>Bile duct disorders, yellowing of the skin due to liver problems, liver tissue damage and inflammation of the liver.</li><li>Itching, rash, hair loss, acne, increased sweating.</li><li>Pain in joints, limbs, back and feet, muscle spasms.</li><li>Insufficient function of the kidneys, reduced production of urine, impaired or painful urination.</li><li>General weakness, fever, collection of fluid in your body, pain and discomfort, increase of the enzyme alkaline phosphatase in your blood, weight gain, feeling of temperature disturbed.</li></ul><p><strong>&nbsp;Uncommon side effects (may affect up to 1 in 100 people):</strong></p><ul><li>Changes in blood clotting, reduction in the number of all types of blood cells (seen in blood tests).</li><li>Dehydration.</li><li>Reduced protein or sugar in the blood, increased phosphate in the blood.</li><li>Coma, bleeding in the brain, stroke, paralysis, brain disorder, speech and language abnormalities, memory problems.</li><li>Opacity of the eye lens.</li><li>Impaired hearing.</li><li>Irregular heartbeat, stop of heartbeat, reduced performance of your heart, disorder of the heart muscle, enlargement of the heart muscle, stronger heartbeat, abnormal ECG, heart rate and pulse abnormal.</li><li>Blood clot in a vein of a limb, shock.</li><li>Difficulties in breathing, respiratory tract disorders, asthma.</li><li>Obstruction of the gut, increased blood level of the enzyme amylase, reflux of stomach content in your throat, delayed emptying of the stomach.</li><li>Inflammation of the skin, burning sensation in the sunlight.</li><li>Joint disorders.</li><li>Inability to urinate, painful menstruation and abnormal menstrual bleeding.</li><li>Multiple organ failure, flu-like illness, increased sensitivity to heat and cold, feeling of pressure on your chest, jittery or abnormal feeling, increase of the enzyme lactate dehydrogenase in your blood, weight loss.</li></ul><p><strong>Rare side effects (may affect up to 1 in 1,000 people):</strong></p><ul><li>Small bleedings in your skin due to blood clots.</li><li>Increased muscle stiffness.</li><li>Deafness.</li><li>Collection of fluid around the heart.</li><li>Acute breathlessness.</li><li>Cyst formation in your pancreas.</li><li>Problems with blood flow in the liver.</li><li>Serious illness with blistering of skin, mouth, eyes and genitals; increased hairiness.</li><li>Thirst, fall, feeling of tightness in your chest, decreased mobility, ulcer.</li></ul><p><strong>Very rare side effects (may affect up to 1 in 10,000 people):</strong></p><ul><li>Muscular weakness.</li><li>Abnormal heart scan.</li><li>Liver failure.</li><li>Painful urination with blood in the urine.</li><li>Increase of fat tissue.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Use all the prolonged-release hard capsules within 1 year of opening the aluminum wrapping.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tacrolimus.</p><p>Each prolonged-release hard capsule of Advagraf<strong> </strong>0.5 mg Prolonged-release Hard Capsules contains 0.5 mg tacrolimus.</p><p>Each prolonged-release hard capsule of Advagraf<strong> </strong>1 mg Prolonged-release Hard Capsules contains 1 mg tacrolimus.</p><p>Each prolonged-release hard capsule of Advagraf<strong> </strong>3 mg Prolonged-release Hard Capsules contains 3 mg tacrolimus.</p><p>Each prolonged-release hard capsule of Advagraf<strong> </strong>5 mg Prolonged-release Hard Capsules contains 5 mg tacrolimus.</p><p>The other ingredients are: <em>Capsule content:</em> Hypromellose, ethylcellulose, lactose monohydrate and magnesium stearate. <em>Capsule shell:</em> Titanium dioxide, yellow iron oxide, red iron oxide, gelatin and sodium lauryl sulfate. <em>Printing ink:</em> Shellac, lecithin (soya), simethicone, ferric oxide red and hydroxypropyl cellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Advagraf 0.5 mg Prolonged-release Hard Capsules are hard capsules imprinted in red with “0.5 mg” on the light yellow capsule cap and “*  647” on the orange capsule body, containing white powder in PVC/PVDC-aluminum blisters wrapped in an aluminum pouch with a desiccant.

Advagraf 1 mg Prolonged-release Hard Capsules are hard capsules imprinted in red with “1 mg” on the white capsule cap and “*  677” on the orange capsule body, containing white powder in PVC/PVDC-aluminum blisters wrapped in an aluminum pouch with a desiccant.

Advagraf 3 mg Prolonged-release Hard Capsules are hard capsules imprinted in red with “3 mg” on the orange capsule cap and “*  637” on the orange capsule body, containing white powder in PVC/PVDC-aluminum blisters wrapped in an aluminum pouch with a desiccant.

Advagraf 5 mg Prolonged-release Hard Capsules are hard capsules imprinted in red with “5 mg” on the greyish red capsule cap and “*  687” on the orange capsule body, containing white powder in PVC/PVDC-aluminum blisters wrapped in an aluminum pouch with a desiccant.

Pack size: 100 Prolonged-release Hard Capsules (2 aluminum pouches, each aluminum pouch contains 50 Prolonged-release Hard Capsules).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />Astellas Ireland Co. Ltd.<br />Killorglin Co. Kerry V93 FC86,<br />Ireland</p><p><strong>Under license from</strong><br />Astellas Pharma International B.V.<br />Sylviusweg 62<br />2333BE Leiden<br />The Netherlands</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 This leaflet was last revised in 12/2023; version number SA2.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أدڤاغراف على المادة الفعالة تاكروليموس. وهو دواء كابت للمناعة. بعد زرع العضو (الكبد، الكلى)، سيحاول جهاز المناعة لديك رفض العضو الجديد. يستخدم أدڤاغراف للسيطرة على رد الفعل المناعي لجسمك، مما يمكن جسمك من تقبل العضو المزروع.</p><p dir="RTL">يمكن أيضاً أن يعطى أدڤاغراف للسيطرة على رد الفعل المناعي بعد الزرع في حال الرفض المستمر للكبد، الكلى، القلب المزروع أو أي عضو آخر عندما لا تتمكن أي علاجات تناولتها سابقاً من السيطرة على هذه الاستجابة المناعية بعد الزرع.</p><p dir="RTL">يستخدم أدڤاغراف للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أدڤاغراف</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية (فرط الحساسية) لتاكروليموس أو لإحدى المواد المستخدمة في تركيبة أدڤاغراف. (انظر القسم 6).</li><li>إذا كنت تعاني من حساسية لسيروليموس أو إلى أي من المضادات الحيوية الماكروليدية (مثل الإريثروميسين، كلاريثروميسين، جوساميسين).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات&nbsp;</strong><br />يحتوي كل من بروغراف وأدڤاغراف على المادة الفعالة تاكروليموس. ومع ذلك، فإن أدڤاغراف يؤخذ مرة واحدة يومياً، في حين يؤخذ بروغراف مرتين يومياً. وذلك لأن كبسولات أدڤاغراف تمنح إطلاق ممتد (إطلاق أبطأ على فترة أطول) للتاكروليموس. إن أدڤاغراف وبروغراف ليسا قابلان للاستخدام المتبادل.</p><p dir="RTL">أخبر طبيبك أو الصيدلي قبل تناول أدڤاغراف:</p><ul dir="rtl"><li>إذا كنت تأخذ أي من الأدوية المذكورة أدناه في القسم &quot;الأدوية الأخرى وأدڤاغراف&quot;.</li><li>إذا كنت تعاني أو عانيت من مشاكل في الكبد.</li><li>إذا كنت تعاني من الإسهال لأكثر من يوم واحد.</li><li>إذا كنت تشعر بآلام شديدة في البطن مصحوبة أو غير مصحوبة بأعراض أخرى، مثل القشعريرة، الحمى، الغثيان أو القيء.</li><li>إذا كان لديك تغير في النشاط الكهربي لقلبك، يسمى &quot;إطالة فترة QT&quot;.</li><li>إذا كنت مصاب أو أصبت سابقاً بتلف بالشريان الأصغر، والمعروف باسم اعْتِلالُ&nbsp;الأَوعِيَةِ&nbsp;الدَّقيقَةِ&nbsp;الخُثارِيّ/ اعتلال الفرفرية قليلة الصفيحات الخثارية/ المتلازمة&nbsp;الانحلالية الدموية البولية. أخبر طبيبك إذا ظهر لديك حمى، كدمات تحت الجلد (والتي قد تظهر على شكل بقع حمراء)، تعب غير مفسر، ارتباك، اصفرار الجلد أو العينين، انخفاض كمية التبول، فقدان الرؤية والنوبات (انظر القسم 4). قد تزيد نسبة حدوث الأعراض المذكورة في حال تناول تاكروليموس مع ساروليماس أو إيفاروليماس.</li></ul><p dir="RTL">الرجاء تجنب تناول أي أدوية عشبية مثل عشبة سانت جونز (هيوفاريقفون&nbsp;مثقب) أو أي مستحضرات عشبية لأن ذلك من الممكن أن يؤثر على فعالية وجرعة أدڤاغراف التي تحتاج تناولها.</p><p dir="RTL">إذا كنت في شك الرجاء الاتصال بالطبيب قبل تناول أي مستحضرات أو أدوية عشبية.</p><p dir="RTL">قد يحتاج طبيبك إلى تعديل جرعتك من أدڤاغراف.</p><p dir="RTL">يجب أن تبقي على اتصال منتظم مع طبيبك. قد يحتاج طبيبك من وقت لآخر للقيام بفحوصات الدم، البول، القلب، العين لتحديد الجرعة المناسبة من أدڤاغراف.</p><p dir="RTL">يجب عليك أن تقلل من تعرضك لأشعة الشمس والأشعة فوق البنفسجية أثناء تناول أدڤاغراف. وذلك لأن كابتات المناعة قد تزيد من خطر الإصابة بسرطان الجلد. قم بارتداء الملابس الواقية المناسبة واستخدام الكريم الواقي من الشمس بمعامل حماية مرتفع.</p><p dir="RTL"><strong>احتياطات أثناء التعامل&nbsp;</strong><br />يجب الحذر من الاتصال المباشر أثناء التحضير مع أي من أجزاء جسمك مثل الجلد أو العينين، أو التنفس في محاليل الحقن، المسحوق أو الحبيبات الموجودة في المستحضرات التي تحتوي مادة تاكروليموس. في حال حدوث أي تواصل، قم بغسل الجلد والعينين.</p><p dir="RTL"><strong>الأطفال والمراهقين&nbsp;</strong><br />لا يوصى باستخدام أدڤاغراف للأطفال والمراهقين دون سن 18 سنة.</p><p dir="RTL"><strong>الأدوية الأخرى وأدڤاغراف&nbsp;</strong><br />يجب استشارة طبيبك أو الصيدلي إذا كنت تأخذ أو أخذت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية والمستحضرات العشبية.</p><p dir="RTL">لا يوصى بتناول أدڤاغراف مع سيكلوسبورين (دواء آخر يستخدم للوقاية من رفض زرع الأعضاء).</p><p dir="RTL">إذا كنت بحاجة لرؤية طبيب أخر غير اختصاصي الزراعة، أخبره بأنك تتناول تاكروليموس. قد يحتاج طبيبك إلى استشارة اختصاصي الزراعة الخاص بك إذا كنت بحاجة إلى استخدام دواء آخر من الممكن أن يزيد أو يقلل من مستوى تاكروليموس في الدم.</p><p dir="RTL">يمكن أن تتأثر مستويات أدڤاغراف في الدم ببعض الأدوية الأخرى التي تأخذها، كما ويمكن أن تتأثر مستويات الأدوية الأخرى في الدم بأخذ أدڤاغراف، والذي قد يتطلب قطع العلاج أو زيادة أو إنقاص جرعة أدڤاغراف.</p><p dir="RTL">عانى بعد المرضى من ارتفاع في مستوى تاكروليموس في الدم خلال تناولهم أدوية أخرى. من الممكن أن يؤدي ذلك إلى أعراض جانبية خطيرة، مثل مشاكل في الكلى، الجهاز العصبي وعدم انتظام النظم القلبي (انظر القسم 4).</p><p dir="RTL">من الممكن حدوث تأثير على مستويات أدڤاغراف في الدم بعد البدء بتناول أدوية أخرى بفترة زمنية قصيرة، ولذلك قد تحتاج إلى مراقبة مستوى أدڤاغراف في الدم لديك بشكل منتظم خلال الأيام القليلة الأولى من بدء تناول دواء آخر وبشكل منتظم عندما يستمر العلاج بأدوية أخرى. من الممكن أن تسبب أدوية أخرى انخفاض مستوى تاكروليموس في الدم، والذي من الممكن أن يزيد من خطر رفض العضو المزروع. بالأخص، يجب أن تخبر طبيبك إذا كنت تأخذ أو أخذت مؤخراً أدوية مثل:</p><ul dir="rtl"><li>الأدوية المضادة للفطريات والمضادات الحيوية، وخاصة ما يسمى المضادات الحيوية الماكروليدية التي تستخدم لعلاج العدوى مثل الكيتوكونازول، الفلوكونازول، الإيتراكونازول، بوساكونازول، الفوريكونازول، الكلوتريمازول، الإيزافوكونازول، ميكونازول، الكاسبوفنجين، تيليثروميسين، الإيريثروميسين، الكلاريثروميسين، الجوساميسين، الأزيثروميسين، الريفامبيسين، ريفابوتين، إيزونيازيد وفلوكلوكساسيلين.</li><li>ليتيرموڤر، يستخدم لمنع المرض الذي يسببه الفَيروسُ المُضَخِّمُ للخَلاَيا البَشَرِيَّة.</li><li>مثبطات بروتياز فيروس نقص المناعة البشرية (متل ريتونافير، نلفينافير، ساكوينافير)، الدواء المعزز كوبيسيستات، وتوليفة الأقراص، الأدوية غير النيوكليوزيدية المضادة لأنزيم المنتسخة المعاكس لفيروس نقص المناعة البشرية (إيفافيرينز، إترافيرين، نيفيرابين) التي تستخدم لعلاج عدوى فيروس نقص المناعة البشرية.</li><li>مثبطات بروتياز فيروس الالتهاب الكبدي ج) مثل التيلابريفير، بوسيبريفير وتوليفة أومبيتاسفير/باريتابريفير/ريتونافير مع أو بدون داسابوفير، إلباسفير/جرازوبريفير، وجليكابريفير/بابرينتاسفير(، التي تستخدم لعلاج عدوى التهاب الكبد الوبائي.</li><li>نيلوتينيب وإيماتينيب، أديلاليسيب، سيريتينيب، كريزوتينيب، أبالوتامايد، إينزالوتامايد، أو ميتُوتان (تستخدم لعلاج نوع معين من السرطان).</li><li>حمض الميكوفنوليك، يستخدم لتثبيط جهاز المناعة لمنع رفض زراعة العضو.</li><li>أدوية علاج قرحة المعدة وارتجاع الحمض (مثل أوميبرازول، لانزوبرازول، أو سيميتيدين).</li><li>مضادات القيء، التي تستخدم لعلاج الغثيان والقيء (مثل ميتوكلوبراميد).</li><li>سيسابريد أو هيدروكسيد المغنيسيوم والألومنيوم المضاد الحموضة، الذي يستخدم لعلاج الحرقة.</li><li>حبوب منع الحمل أو العلاجات الهرمونية الأخرى بإيثينيل إستراديول، العلاج الهرموني بدانازول.</li><li>الأدوية المستخدمة لعلاج ارتفاع ضغط الدم أو مشاكل القلب مثل نيفيديبين، نيكارديبين، ديلتيازيم وفيراباميل.</li><li>الأدوية المضادة لاضطراب نظم القلب (اميودارون) الذي يستخدم للسيطرة على عدم انتظام ضربات القلب (دقات غير متكافئة للقلب).</li><li>الأدوية المعروفة باسم &quot;الستاتينات&quot; المستخدمة في علاج ارتفاع الكولسترول والدهون الثلاثية.</li><li>الكاربامازبين، الفينيتوين أو الفينوباربيتال المستخدمين لعلاج الصرع.</li><li>ميتاميزول، المستخدم لعلاج الألم والحمى.</li><li>ستيرويدات بريدنيزولون القشرية والميثيلبريدنيزولون والذين ينتموا إلى مجموعة الأدوية المعروفة بالستيرويدات القشرية المستخدمة لعلاج الالتهابات أو تثبيط الجهاز المناعي (مثل زراعة الأعضاء).</li><li>مضاد الإكتئاب نيفازودون.</li><li>المستحضرات العشبية التي تحتوي على نبتة القديس يوحنا (هيبريكوم بيرفوراتوم) أو مستخلصات شيساندرا سفينانثيرا.</li><li>كانابيديول (استخدامات متعددة من ضمنها علاج التشنجات).</li></ul><p dir="RTL">أخبر طبيبك إذا كنت تتلقى العلاج الالتهاب الكبدي ج. قد يؤدي علاج الالتهاب الكبدي ج بالأدوية إلى تغيير وظيفة الكبد لديك وقد يؤثر على مستويات تاكروليموس في الدم. قد تنقص أو تزيد مستويات تاكروليموس في الدم اعتماداً على الأدوية الموصوفة للالتهاب الكبدي ج. قد يحتاج طبيبك لمراقبة مستويات تاكروليموس في الدم عن قرب وبتعديلات ضرورية لجرعة أدڤاغراف قبل بدء علاج الالتهاب الكبدي ج.</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ أو بحاجة إلى أخذ إيبوبروفين (دواء يستخدم لعلاج الحمى، الالتهاب والألم)، المضادات الحيوية (كوتريموكسازول، ڤانكومايسين أو المضادات الحيوية الأمينوجليكوزايدية مثل جنتامايسين)، الأمفوتيريسين ب (المستخدم لعلاج العدوى الفطرية) أو مضادات الفيروسات (المستخدمة لعلاج العدوى الفيروسية مثل أسيكلوڤير، جانسيكلوڤير، سايدوفوڤير أو فوسكارنيت). قد يؤدي تناول هذه الأدوية مع أدڤاغراف إلى تفاقم مشاكل الكلى أو الجهاز العصبي.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول ساروليماس أو إيفاروليماس. قد يزداد خطر حدوث اعْتِلالُ&nbsp;الأَوعِيَةِ&nbsp;الدَّقيقَةِ&nbsp;الخُثارِيّ، الفُرْفُرِيَّةُ القَليلَةُ الصُّفَيحاتِ الخُثارِيَّة والمتلازمة&nbsp;الانحلالية الدموية البولي عند تناول تاكروليموس بالتزامن مع ساروليماس أو إيفاروليماس (انظر القسم 4).</p><p dir="RTL">أثناء تناولك لأدڤاغراف، يحتاج طبيبك أيضاً لمعرفة ما إذا كنت تأخذ مكملات البوتاسيوم أو بعض مدرات البول المستخدمة لفشل القلب، ارتفاع ضغط الدم ومرض الكلى، (مثل أميلوريد، تريامتيران أو السبيرونولاكتون)، أو المضادات الحيوية التي تزيد من مستوى البوتاسيوم في الدم مثل تريميثوبريم أو كوتريموكسازول أو الأدوية المضادة للالتهابات اللاستيرويدية (مثل إيبوبروفين) التي تستخدم لعلاج الحمى، الالتهاب والألم، أو مضادات التخثر (مرققات الدم)، أو الأدوية التي تؤخذ عن طريق الفم لعلاج السكري.</p><p dir="RTL">أخبر طبيبك مسبقاً إذا كنت بحاجة إلى أية لقاحات.</p><p dir="RTL"><strong>أدڤاغراف مع الطعام والشراب&nbsp;</strong><br />تجنب تناول الجريب فروت (كعصير أيضاً)، أثناء العلاج بأدڤاغراف، لأنه يمكن أن يؤثر على مستوياته في الدم.</p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة&nbsp;</strong><br />يرجى استشارة طبيبك إذا كنت حاملاً، تعتقدين أنك كذلك أو تخططين لذلك قبل تناول أدڤاغراف.</p><p dir="RTL">يفرز أدڤاغراف في حليب الثدي. لذلك، يجب أن لا تقومي بالإرضاع أثناء استخدام أدڤاغراف.</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp;</strong><br />لا تقم بالقيادة أو استخدام أي أدوات أو آلات إذا كنت تشعر بالدوار أو النعاس، أو لديك مشاكل في الرؤية بوضوح بعد تناول أدڤاغراف. تكون هذه الآثار أكثر تكراراً إذا كنت تشرب الكحول.</p><p dir="RTL"><strong>&nbsp;يحتوي </strong><strong>أدڤاغراف على اللاكتوز أحادي الماء، الصوديوم والليسيثين (الصويا)&nbsp;</strong><br />يحتوي أدڤاغراف على اللاكتوز أحادي الماء. تحتوي كل كبسولة صلبة ممتدة الإطلاق من أدڤاغراف 0.5 ملغم، 1 ملغم، 3 ملغم و5 ملغم كبسولات صلبة ممتدة الإطلاق على 53,64 ملغم، 107,28 ملغم، 321,84 ملغم أو 536,4 ملغم لاكتوز أحادي الماء؛ على التوالي. إذا تم إخبارك من طبيبك أن لديك عدم تحمل لبعض السكريات، تواصل مع طبيك قبل تناول هذا المستحضر الدوائي.</p><p dir="RTL">يحتوي أدڤاغراف على الصوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل كبسولة صلبة ممتدة الإطلاق، وبذلك يمكن اعتباره &rsquo; خالٍ من الصوديوم&lsquo; بشكل أساسي.</p><p dir="RTL">يحتوي حبر الطباعة المستخدم في أدڤاغراف كبسولات صلبة ممتدة الإطلاق على الليسيثين (الصويا). تحتوي كل كبسولة صلبة ممتدة الإطلاق من أدڤاغراف 0.5 ملغم، 1 ملغم، 3 ملغم و5 ملغم كبسولات صلبة ممتدة الإطلاق على 0,0009 ملغم، 0,0008 ملغم، 0,0013 ملغم أو 0,0015 ملغم الليسيثين (الصويا)؛ على التوالي. إذا كانت لديك حساسية للفول السوداني أو الصويا، تحدث إلى طبيبك لتحديد إذا كان يجب عليك استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائماً أدڤاغراف تماماً كما أخبرك الطبيب. يرجى استشارة الطبيب أو الصيدلي إذا كنت غير متأكد. يجب ان يتم وصف هذا الدواء لك فقط عن طريق طبيب ذو خبرة في علاج مرضى زرع الأعضاء.</p><p dir="RTL">تأكد من تناولك نفس الدواء من تاكروليموس في كل مرة تقوم بصرف الوصفة الطبية، إلا إذا وافق اختصاصي الزرع الخاص بك على التغيير لنوع آخر من دواء تاكروليموس. ينبغي أخذ هذا الدواء مرة واحدة يومياً. إذا لم يكن شكل هذا الدواء هو نفسه كالمعتاد، أو إذا تغيرت تعليمات الجرعة، تحدث إلى طبيبك أو الصيدلي في أقرب وقت ممكن للتأكد من أن لديك الدواء المناسب.</p><p dir="RTL">سيتم تحديد الجرعة الابتدائية لمنع رفض العضو المزروع الخاص بك من قبل طبيبك بحيث يتم حسابها اعتماداً على وزن جسمك. بشكل عام ستكون الجرعات الأولية اليومية مباشرة بعد الزرع بين 0.10 إلى 0.30 ملغم لكل كيلوغرام من وزن الجسم يومياً اعتماداً على العضو المزروع. يمكن أن تستخدم هذه الجرعات ذاتها عند علاج الرفض.</p><p dir="RTL">تعتمد جرعتك على حالتك العامة وعلى أدوية كبت المناعة الأخرى التي تتناولها.</p><p dir="RTL">بعد بدء علاجك بأدڤاغراف، سيتم إجراء فحوصات دم متكررة لك من قبل طبيبك لتحديد الجرعة الصحيحة. بعد ذلك سيطلب منك طبيبك إجراء فحوصات دم منتظمة لتحديد الجرعة الصحيحة وتعديل الجرعة من وقت لآخر. سيقوم طبيبك عادة بخفض جرعتك من أدڤاغراف ما أن تستقر حالتك. سيخبرك طبيبك بعدد الكبسولات التي يجب أن تتناولها بالتحديد.</p><p dir="RTL">ستحتاج إلى تناول أدڤاغراف يومياً طوال المدة التي تحتاج فيها إلى كبت المناعة لمنع رفض العضو المزروع. يجب أن تبقى على اتصال منتظم مع طبيبك.</p><p dir="RTL">يؤخذ أدڤاغراف عن طريق الفم مرة واحدة يومياً في الصباح. تناول أدڤاغراف على معدة فارغة أو بعد ساعتين إلى ثلاث ساعات من تناول الوجبة. انتظر على الأقل ساعة واحدة قبل تناول الوجبة التالية. تناول الكبسولات فوراً بعد إخراجها من الشريط. يجب ابتلاع الكبسولات بأكملها مع كوب من الماء. لا تبتلع المادة المجففة الموجودة في غلاف الألومنيوم.</p><p dir="RTL"><strong>إذا تناولت أدڤاغراف أكثر من اللازم&nbsp;</strong><br />اتصل بطبيبك أو قسم الطوارئ في أقرب مستشفى لديك على الفور إذا تناولت الكثير من أدڤاغراف دون قصد.</p><p dir="RTL"><strong>إذا نسيت تناول أدڤاغراف&nbsp;</strong><br />إذا نسيت تناول كبسولات أدڤاغراف في الصباح، تناولها في أقرب وقت ممكن في نفس اليوم. لا تأخذ جرعة مضاعفة في صباح اليوم التالي.</p><p dir="RTL"><strong>إذا توقفت عن تناول أدڤاغراف&nbsp;</strong><br />قد يزيد توقفك عن العلاج بأدڤاغراف من خطر رفض العضو المزروع لديك. لا توقف علاجك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">استشر طبيبك أو الصيدلي إذا كان لديك أية أسئلة إضافية حول كيفية استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب أدڤاغراف آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">يقلل أدڤاغراف من آلية جسمك الدفاعية (جهاز المناعة)، والتي لن تكون جيدة كما ينبغي لمحاربة العدوى. لذا قد تكون أكثر عرضة للعدوى أثناء تناول أدڤاغراف.</p><p dir="RTL">قد تكون بعض العدوات خطيرة أو قاتلة وقد تشمل العدوى التي تسببها البكتيريا، الفيروسات، الفطريات، الطفيليات أو العدوات الأخرى.</p><p dir="RTL">أخبر طبيبك على الفور إذا ظهرت لديك علامات العدوى التي تشمل:</p><ul dir="rtl"><li>حمى، سعال، التهاب الحلق، الشعور بالضعف أو التعب العام.</li><li>فقدان الذاكرة، مشاكل في التفكير، صعوبة في المشي- أو فقدان الرؤية- قد يكون ذلك بسبب عدوى نادرة جداً، خطيرة في الدماغ، والتي قد تكون قاتلة (اعتلال بيضاء الدماغ متعدد البؤر التقدمي).</li></ul><p dir="RTL">قد تحدث آثار جانبية شديدة، بما في ذلك ردود الفعل التحسسيّة والتأقيّة. تم الإبلاغ عن تكون أورام حميدة وخبيثة بعد العلاج بأدڤاغراف.</p><p dir="RTL"><strong><em>أخبر طبيبك على الفور في حال اشتباه إنك قد تعاني من الآثار الجانبية الخطيرة التالية:&nbsp;</em></strong><br /><strong>آثار جانبية خطيرة شائعة (قد يؤثر فيما يصل إلى 1 من كل 10 أشخاص): </strong></p><ul dir="rtl"><li>ثقب الجهاز الهضمي: آلام شديدة في البطن مصحوبة أو غير مصحوبة بأعراض أخرى مثل النفضات، الحمى، الغثيان أو التقيؤ.</li><li>وظائف غير كافية للعضو المزروع.</li><li>تغييم الرؤية.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة غير شائعة (قد يؤثر فيما يصل إلى 1 من كل 100 أشخاص): </strong></p><ul dir="rtl"><li>اعتلال الأوعية الدقيقة الخثاري (تلف في أصغر الأوعية الدموية) بما في ذلك المتلازمة&nbsp;الانحلالية الدموية البولية، حالة تشمل الأعراض التالية: قلة وعدم إخراج البول (الفشل الكلوي الحاد)، التعب الحاد، اصفرار الجلد أو العينين (اليرقان) والكدمات غير الطبيعية أو النزيف وعلامات العدوى.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة نادرة (قد يؤثر فيما يصل إلى 1 من كل 1000 أشخاص): </strong></p><ul dir="rtl"><li>الفرفرية قليلة الصفيحات الخثارية وهي حالة تشمل تلف في أصغر الأوعية الدموية وتتميز بالحمى وكدمات تحت الجلد والتي قد تظهر كنقاط حمراء صغيرة جداً، مع أو بدون تعب شديد غير مبرر، ارتباك، اصفرار الجلد أو العينين (اليرقان)، مع أعراض الفشل الكلوي الحاد (قلة وعدم إخراج البول)، فقدان الرؤية والنوبات.</li><li>تقشر الانسجة المتموتة البشرويَة التسمُمي: تآكل وظهور تقرحات في الجلد أو الأغشية المخاطية، احمرار وتورم الجلد الذي يمكن أن ينفصل في أجزاء كبيرة من الجسم.</li><li>العمى.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة نادرة جداً (قد يؤثر فيما يصل إلى 1 من كل 10000 أشخاص): </strong></p><ul dir="rtl"><li>متلازمة ستيفنز جونسون: آلام غير مبررة في مساحات واسعة من الجلد، تورم الوجه، مرض شديد مع ظهور تقرحات في الجلد، الفم، العينين، والأعضاء التناسلية، الشرى، تورم اللسان، انتشار طفح جلدي أحمر أو أرجواني، تقشر الجلد.</li><li>مرض تورساد دي بوانتس<em>:</em> تغير في وتيرة ضربات القلب التي يمكن أن تكون مصحوبة أو غير مصحوبة بأعراض، مثل ألم في الصدر (الذبحة الصدرية)، فقدان الوعي، الدوار أو الغثيان، الخفقان (شعور بضربات القلب) وصعوبة في التنفس.</li></ul><p dir="RTL"><strong>آثار جانبية خطيرة - </strong><strong>غير معروفة</strong> <strong>التكرار</strong> <strong>(لا يمكن تقدير التكرار من البيانات المتاحة):</strong></p><ul dir="rtl"><li>العدوى الانتهازية (بكتيرية، فطرية، فيروسية، وأواليه): إسهال لفترة طويلة، الحمى والتهاب الحلق.</li><li>تم الإبلاغ عن حدوث أورام حميدة وخبيثة بعد العلاج نتيجة لكبت المناعة.</li><li>تم الابلاغ عن حالات من عدم تنسج خلايا الدم الحمراء النقي (انخفاض شديد جداً في عدد خلايا الدم الحمراء)، فقر الدم الانحلالي (انخفاض عدد خلايا الدم الحمراء بسبب التحلل غير الطبيعي المترافق مع التعب) وقلة العدلات الحموية (نقص في نوع من خلايا الدم البيضاء التي تحارب العدوى، المصحوبة بحمى). من غير المعروف تكرار حدوث هذه الآثار الجانبية بالتحديد. قد لا تعاني من الأعراض أو اعتماداً على شدة الحالة فإنك قد تشعر بـ: التعب، الخمول، شحوب غير طبيعي في الجلد، ضيق في التنفس، دوخة، صداع، آلام في الصدر وبرودة في اليدين والقدمين.</li><li>حالات من ندرة المحببات (انخفاض شديد في عدد خلايا الدم البيضاء المصحوب بتقرحات في الفم، الحمى والإصابة بالعدوى). قد لا تظهر لديك أية أعراض أو قد تشعر بحمى مفاجئة، نفضات أو التهاب الحلق.</li><li>ردود فعل تحسسية وتأقيه مع الأعراض التالية: طفح جلدي مع حكة مفاجئة (شرى)، تورم في اليدين، القدمين، الكاحل، الوجه، الشفتين، الفم أو الحلق (الذي قد يسبب صعوبة في البلع أو التنفس) وقد تشعر بفقدان الوعي.</li><li>متلازمة اعتلال الدماغ الخلفي القابل للإصلاح: الصداع، ارتباك، تغيرات المزاج، نوبات، واضطرابات بصرية. قد تدل هذه العلامات على وجود مرض يسمى متلازمة اعتلال الدماغ الخلفي القابل للإصلاح، الذي تم الإبلاغ عنه في بعض المرضى الذين تم علاجهم بتاكروليموس.</li><li>الاعتلال العصبي البصري (اضطراب في العصب البصري): مشاكل في الرؤية مثل تغييم الرؤية، تغيرات في رؤية الألوان، صعوبة في رؤية التفاصيل أو انحصار مدى الرؤية لديك.</li></ul><p dir="RTL"><strong><em>الآثار الجانبية المدرجة أدناه قد تحدث أيضاً بعد تناولك </em></strong><strong>أدڤاغراف</strong><strong><em> وقد تكون خطيرة:&nbsp;</em></strong><br /><strong>الآثار</strong><strong> الجانبية الشائعة جداً (قد تؤثر على أكثر من شخص من كل 10 أشخاص):</strong></p><ul dir="rtl"><li>زيادة نسبة السكر في الدم، السكري، زيادة البوتاسيوم في الدم.</li><li>صعوبة في النوم.</li><li>الارتعاش، الصداع.</li><li>ارتفاع ضغط الدم.</li><li>فحوصات وظائف الكبد المخبرية غير طبيعية .</li><li>الإسهال، الغثيان.</li><li>مشاكل في الكلى.</li></ul><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى شخص من كل 10 أشخاص):</strong></p><ul dir="rtl"><li>انخفاض تعداد خلايا الدم (الصفيحات، خلايا الدم الحمراء أو البيضاء)، زيادة في تعداد كريات الدم البيضاء، تغيرات في &nbsp;تعداد خلايا الدم الحمراء (تظهر في فحوصات الدم المخبرية).</li><li>انخفاض المغنيسيوم، الفوسفات، البوتاسيوم، الكالسيوم أو الصوديوم في الدم، زيادة السوائل، زيادة حمض اليوريك أو الدهون في الدم، نقصان الشهية، زيادة حموضة الدم، تغيرات أخرى في أملاح الدم (تظهر في فحوصات الدم المخبرية).</li><li>أعراض القلق، الارتباك والتوهان، الاكتئاب، تغيرات في المزاج، الكوابيس، الهلوسة، الاضطرابات العقلية.</li><li>نوبات، اضطرابات في الوعي، وخز وتنميل (مؤلمة في بعض الأحيان) في اليدين والقدمين، دوخة، ضعف في القدرة على الكتابة، اضطرابات الجهاز العصبي.</li><li>زيادة الحساسية للضوء، اضطرابات العين.</li><li>صوت طنين في الأذنين.</li><li>انخفاض تدفق الدم في الأوعية القلبية، ضربات قلب أسرع.</li><li>النزف، انسداد جزئي أو كامل في الأوعية الدموية، انخفاض ضغط الدم.</li><li>ضيق في التنفس، اضطرابات في الأنسجة التنفسية في الرئة، تجمع السوائل حول الرئة، التهاب البلعوم، السعال، أعراض تشبه الانفلونزا.</li><li>الالتهاب أو القرحة مما يسبب آلام في البطن أو إسهال، نزف في المعدة، التهاب أو قرحة في الفم، تجمع السوائل في البطن، قيء، آلام في البطن، عسر الهضم، إمساك، ريح، انتفاخ، رخاوة البراز ومشاكل في المعدة.</li><li>اضطرابات القناة الصفراوية، اصفرار الجلد بسبب مشاكل في الكبد، تلف أنسجة الكبد والتهاب الكبد.</li><li>حكة، طفح جلدي، فقدان الشعر، حب الشباب، زيادة التعرق.</li><li>ألم في المفاصل، الأطراف، الظهر والأقدام، وتشنجات في العضلات.</li><li>قصور وظائف الكلى، انخفاض إنتاج البول، اعتلال أو ألم عند التبول.</li><li>ضعف عام، حمى، تجمع السوائل في جسمك، ألم وشعور بعدم الراحة، وزيادة إنزيم الفوسفاتاز القلوي في دمك، زيادة الوزن، شعور باضطراب درجة الحرارة.</li></ul><p dir="RTL"><strong>الآثار الجانبية</strong><strong> غير الشائعة (تؤثر على ما يصل إلى شخص من كل 100 شخص):</strong></p><ul dir="rtl"><li>تغيرات في تخثر الدم، انخفاض في عدد جميع أنواع خلايا الدم (تظهر في فحوصات الدم المخبرية).</li><li>جفاف.</li><li>انخفاض البروتين أو السكر، زيادة الفوسفات في الدم.</li><li>غيبوبة، نزف في الدماغ، سكتة الدماغية، شلل، اضطراب الدماغ، اعتلالات في التحدث واللغة، مشاكل في الذاكرة.</li><li>تغيم عدسة العين.</li><li>ضعف السمع.</li><li>عدم انتظام ضربات القلب، توقف ضربات القلب، انخفاض أداء القلب، اضطراب عضلة القلب، تضخم عضلة القلب، زيادة قوة ضربات القلب، تخطيط كهربية قلب غير طبيعي، معدل ضربات القلب والنبض غير طبيعيان.</li><li>تجلط الدم في الوريد بالأطراف، الصدمة.</li><li>صعوبات في التنفس، اضطرابات في الجهاز التنفسي، الربو.</li><li>انسداد الأمعاء، زيادة مستوى إنزيم الأميلاز في الدم، ارتجاع محتويات المعدة للحلق، تأخر إفراغ المعدة.</li><li>التهاب الجلد، شعور بالحرق عند التعرض لضوء الشمس.</li><li>اضطرابات المفاصل.</li><li>عدم القدرة على التبول، حيض مؤلم ونزف حيضي غير طبيعي.</li><li>فشل أعضاء متعددة، مرض شبيه بالإنفلونزا، زيادة الحساسية للحرارة والبرودة، شعور بضغط على الصدر، شعور بعصبية أو شعور غير طبيعي، ارتفاع إنزيم نازِعة&nbsp;هيدروجينِ&nbsp;اللَاكتات في الدم، فقدان الوزن.</li></ul><p dir="RTL"><strong>الآثار الجانبية</strong><strong> النادرة (قد تؤثر على ما يصل إلى شخص من كل 1000 شخص):</strong></p><ul dir="rtl"><li>نزيف قليل في الجلد بسبب تجلطات الدم.</li><li>زيادة تصلب العضلات.</li><li>الصمم.</li><li>تجمع السوائل حول القلب.</li><li>ضيق النفس الحاد.</li><li>تكون كيس في البنكرياس.</li><li>اضطرابات تدفق الدم في الكبد.</li><li>مرض خطير مع ظهور نفطات في الجلد، الفم، العينين والأعضاء التناسلية؛ زيادة كثافة الشعر.</li><li>العطش، السقوط، الشعور بضيق في الصدر، انخفاض الحركة، القرحة.</li></ul><p dir="RTL"><strong>الآثار الجانبية</strong><strong> النادرة جداً (قد تؤثر على ما يصل إلى شخص من كل 10000 </strong><strong>شخص</strong><strong>):</strong></p><ul dir="rtl"><li>ضعف العضلات.</li><li>تصوير القلب الإشعاعي غير طبيعي.</li><li>فشل الكبد.</li><li>التبول المؤلم مع الدم في البول.</li><li>زيادة الأنسجة الدهنية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">استخدم كافة الكبسولات الصلبة ممتدة الإطلاق خلال سنة واحدة من فتح غلاف الألومنيوم.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي تاكروليموس.</p><p dir="RTL">تحتوي كل كبسولة صلبة ممتدة الإطلاق من أدڤاغراف 0.5 ملغم كبسولات صلبة ممتدة الإطلاق على 0.5 ملغم تاكروليموس.</p><p dir="RTL">تحتوي كل كبسولة صلبة ممتدة الإطلاق من أدڤاغراف 1 ملغم كبسولات صلبة ممتدة الإطلاق على 1 ملغم تاكروليموس.</p><p dir="RTL">تحتوي كل كبسولة صلبة ممتدة الإطلاق من أدڤاغراف 3 ملغم كبسولات صلبة ممتدة الإطلاق على 3 ملغم تاكروليموس.</p><p dir="RTL">تحتوي كل كبسولة صلبة ممتدة الإطلاق من أدڤاغراف 5 ملغم كبسولات صلبة ممتدة الإطلاق على 5 ملغم تاكروليموس.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>محتوى الكبسولة</em>: هايبروميلوز، إيثيل السيلليلوز، لاكتوز أحادي الماء وستيرات المغنيسيوم. <em>غلاف الكبسولة</em>: ثاني أكسيد التيتانيوم، أكسيد الحديد الأصفر، أكسيد الحديد الأحمر، جيلاتين وكبريتات لوريل الصوديوم. <em>حبر الطباعة</em>: شيلاك، ليسيثين (الصويا)، سيميثيكون، أكسيد الحديد الأحمر وهيدروكسي بروبيل السيلليلوز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أدڤاغراف 0.5 ملغم كبسولات صلبة ممتدة الإطلاق هي كبسولات صلبة مطبوع عليها باللون الأحمر&nbsp; <img src="data:image/png;base64,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" alt="" width="50" height="17" vspace="0" hspace="0" border="0" style="width:50px;height:17px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />&nbsp;على غطاء الكبسولة ذات اللون الأصفر الفاتح&nbsp;<img src="data:image/png;base64,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" alt="" width="56" height="13" vspace="0" hspace="0" border="0" style="width:56px;height:13px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /> على جسم الكبسولة البرتقالي، تحتوي على مسحوق أبيض في أشرطة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم مغلفة بكيس من الألومنيوم مع مادة مجففة.</p><p dir="RTL">أدڤاغراف 1 ملغم كبسولات صلبة ممتدة الإطلاق هي كبسولات صلبة مطبوع عليها باللون الأحمر&nbsp;&nbsp;<img src="data:image/png;base64,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" alt="" width="41" height="17" vspace="0" hspace="0" border="0" style="width:41px;height:17px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />&nbsp;على غطاء الكبسولة ذات اللون الأبيض&nbsp;<img src="data:image/png;base64,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" alt="" width="52" height="17" vspace="0" hspace="0" border="0" style="width:52px;height:17px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /> على جسم الكبسولة البرتقالي، تحتوي على مسحوق أبيض في أشرطة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم مغلفة بكيس من الألومنيوم مع مادة مجففة.</p><p dir="RTL">أدڤاغراف 3 ملغم كبسولات صلبة ممتدة الإطلاق هي كبسولات صلبة مطبوع عليها باللون الأحمر&nbsp;<img src="data:image/png;base64,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" alt="" width="41" height="15" vspace="0" hspace="0" border="0" style="width:41px;height:15px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />&nbsp;على غطاء الكبسولة ذات اللون البرتقالي&nbsp;<img src="data:image/png;base64,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" alt="" width="53" height="16" vspace="0" hspace="0" border="0" style="width:53px;height:16px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /> على جسم الكبسولة البرتقالي، تحتوي على مسحوق أبيض في أشرطة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم مغلفة بكيس من الألومنيوم مع مادة مجففة.</p><p dir="RTL">أدڤاغراف 5 ملغم كبسولات صلبة ممتدة الإطلاق هي كبسولات صلبة مطبوع عليها باللون الأحمر&nbsp;<img src="data:image/png;base64,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" alt="" width="42" height="17" vspace="0" hspace="0" border="0" style="width:42px;height:17px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />&nbsp;على غطاء الكبسولة ذات اللون الرمادي المحمر&nbsp;<img src="data:image/png;base64,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" alt="" width="56" height="16" vspace="0" hspace="0" border="0" style="width:56px;height:16px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />&nbsp;على جسم الكبسولة البرتقالي، تحتوي على مسحوق أبيض في أشرطة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم مغلفة بكيس من الألومنيوم مع مادة مجففة.</p><p dir="RTL">حجم العبوة: 100 كبسولة صلبة ممتدة الإطلاق (كيسان من الألومنيوم، يحتوي كل كيس من الألومنيوم على 50 كبسولة صلبة ممتدة الإطلاق).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق&nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية&nbsp;<br />طريق الخرج&nbsp;<br />صندوق بريد 106229&nbsp;<br />الرياض 11666، المملكة العربية السعودية&nbsp;<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +&nbsp;<br />فاكس: 2078170 (11-966) +&nbsp;<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة&nbsp;</strong><br />شركة أستيلاس إيرلندا المحدودة&nbsp;<br />كيلورغلين، مقاطعة كيري، V93 FC86،<br />إيرلندا&nbsp;</p><p dir="RTL"><strong>بترخيص من&nbsp;</strong><br />شركة أستيلاس فارما الدولية المساهمة الخاصة المحدودة&nbsp;<br />سيلڤيوسويج 62&nbsp;<br />2333BE ليدن&nbsp;<br />هولندا</p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الآثار<strong> </strong>الجانبية&nbsp;</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>&nbsp;المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي&nbsp;<br />مركز الاتصال الموحد: 19999&nbsp;<br />البريد الإلكتروني: npc.drug@sfda.gov.sa&nbsp;<br />الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 12/2023، رقم النسخة SA2.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Advagraf 0.5 mg Prolonged-release Hard Capsules


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each prolonged-release hard capsule of Advagraf 0.5 mg Prolonged-release Hard Capsules contains 0.5 mg tacrolimus.

Excipients with known effect: lactose monohydrate, sodium and lecithin (soya)

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release hard capsules.

Hard capsules imprinted in red with “0.5 mg” on the light yellow capsule cap and “*  647” on the orange capsule body, containing white powder.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.</p><p>Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Advagraf is a once-a-day oral formulation of tacrolimus. Advagraf therapy requires careful monitoring by adequately qualified and equipped personnel. This medicinal product should only be prescribed, and changes in immunosuppressive therapy initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients.</p><p>Different oral formulations of tacrolimus should not be substituted without clinical supervision.</p><p>Inadvertent, unintentional or unsupervised switching between different oral formulations of tacrolimus with different release characteristics is unsafe. This can lead to graft rejection or increased incidence of adverse reactions, including under- or overimmunosuppression, due to clinically relevant differences in systemic exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.4 and 4.8). Following conversion to any alternative formulation, therapeutic drug monitoring must be performed and dose adjustments made to ensure that systemic exposure to tacrolimus is maintained.</p><p><strong>Posology</strong><br />The recommended initial doses presented below are intended to act solely as a guideline. Advagraf is routinely administered in conjunction with other immunosuppressive agents in the initial post-operative period. The dose may vary depending upon the immunosuppressive regimen chosen. Advagraf dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring (see below under &ldquo;Therapeutic drug monitoring&rdquo;). If clinical signs of rejection are apparent, alteration of the immunosuppressive regimen should be considered.</p><p>In&nbsp;<em>de novo</em>&nbsp;kidney and liver transplant patients AUC<sub>0-24</sub>&nbsp;of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for the immediate release capsules (Prograf) at equivalent doses. By Day 4, systemic exposure as measured by trough levels is similar for both kidney and liver transplant patients with both formulations. Careful and frequent monitoring of tacrolimus trough levels is recommended in the first two weeks post-transplant with Advagraf to ensure adequate drug exposure in the immediate post-transplant period. As tacrolimus is a substance with low clearance, adjustments to the Advagraf dose regimen may take several days before steady state is achieved.</p><p>To suppress graft rejection, immunosuppression must be maintained; consequently, no limit to the duration of oral therapy can be given.</p><p><u>Prophylaxis of kidney transplant rejection</u><br />Advagraf therapy should commence at a dose of 0.20 - 0.30 mg/kg/day administered once daily in the morning. Administration should commence within 24 hours after the completion of surgery.</p><p>Advagraf doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to Advagraf monotherapy. Post-transplant changes in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Prophylaxis of liver transplant rejection</u><br />Advagraf therapy should commence at a dose of 0.10 - 0.20 mg/kg/day administered once daily in the morning. Administration should commence approximately 12-18 hours after the completion of surgery.</p><p>Advagraf doses are usually reduced in the post-transplant period. It is possible in some cases to withdraw concomitant immunosuppressive therapy, leading to Advagraf monotherapy. Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of tacrolimus and may necessitate further dose adjustments.</p><p><u>Conversion of Prograf-treated patients to Advagraf</u><br />Allograft transplant patients maintained on twice daily Prograf capsules dosing requiring conversion to once daily Advagraf should be converted on a 1:1 (mg:mg) total daily dose basis. Advagraf should be administered in the morning.</p><p>In stable patients converted from Prograf capsules (twice daily) to Advagraf (once daily) on a 1:1 (mg:mg) total daily dose basis, the systemic exposure to tacrolimus (AUC<sub>0-24</sub>) for Advagraf was approximately 10% lower than that for Prograf. The relationship between tacrolimus trough levels (C<sub>24</sub>) and systemic exposure (AUC<sub>0-24</sub>) for Advagraf is similar to that of Prograf. When converting from Prograf capsules to Advagraf, trough levels should be measured prior to conversion and within two weeks after conversion. Following conversion, tacrolimus trough levels should be monitored and if necessary dose adjustments made to maintain similar systemic exposure. Dose adjustments should be made to ensure that similar systemic exposure is maintained.</p><p><u>Conversion from ciclosporin to tacrolimus</u><br />Care should be taken when converting patients from ciclosporin-based to tacrolimus-based therapy (see sections 4.4 and 4.5). The combined administration of ciclosporin and tacrolimus is not recommended. Advagraf therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient. Dosing should be delayed in the presence of elevated ciclosporin blood levels. In practice, tacrolimus-based therapy has been initiated 12 - 24 hours after discontinuation of ciclosporin. Monitoring of ciclosporin blood levels should be continued following conversion as the clearance of ciclosporin might be affected.</p><p><u>Treatment of allograft rejection</u><br />Increased doses of tacrolimus, supplemental corticosteroid therapy, and introduction of short courses of mono-/polyclonal antibodies have all been used to manage rejection episodes. If signs of toxicity such as severe adverse reactions are noted (see section 4.8), the dose of Advagraf may need to be reduced.</p><p><em>Treatment of allograft rejection after kidney or liver transplantation</em><br />For conversion from other immunosuppressants to once daily Advagraf, treatment should begin with the initial oral dose recommended in kidney and liver transplantation respectively for prophylaxis of transplant rejection.</p><p><em>Treatment of allograft rejection after heart transplantation</em><br />In adult patients converted to Advagraf, an initial oral dose of 0.15 mg/kg/day should be administered once daily in the morning.</p><p><em>Treatment of allograft rejection after transplantation of other allografts</em><br />Although there is no clinical experience with Advagraf in lung-, pancreas- or intestine-transplanted patients, Prograf has been used in lung-transplanted patients at an initial oral dose of 0.10 - 0.15 mg/kg/day, in pancreas-transplanted patients at an initial oral dose of 0.2 mg/kg/day and in intestinal transplantation at an initial oral dose of 0.3 mg/kg/day.</p><p><u>Therapeutic drug monitoring</u><br />Dosing should primarily be based on clinical assessments of rejection and tolerability in each individual patient aided by whole blood tacrolimus trough level monitoring.</p><p>As an aid to optimise dosing, several immunoassays are available for determining tacrolimus concentrations in whole blood. Comparisons of concentrations from the published literature to individual values in clinical practice should be assessed with care and knowledge of the assay methods employed. In current clinical practice, whole blood levels are monitored using immunoassay methods. The relationship between tacrolimus trough levels (C<sub>24</sub>) and systemic exposure (AUC&nbsp;<sub>0-24</sub>) is similar between the two formulations Advagraf and Prograf.</p><p>Blood trough levels of tacrolimus should be monitored during the post-transplantation period. Tacrolimus blood trough levels should be determined approximately 24 hours post-dosing of Advagraf, just prior to the next dose. Frequent trough level monitoring in the initial two weeks post transplantation is recommended, followed by periodic monitoring during maintenance therapy. Blood trough levels of tacrolimus should also be closely monitored following conversion from Prograf to Advagraf, dose adjustments, changes in the immunosuppressive regimen, or co-administration of substances which may alter tacrolimus whole blood concentrations (see section 4.5). The frequency of blood level monitoring should be based on clinical needs. As tacrolimus is a substance with low clearance, following adjustments to the Advagraf dose regimen it may take several days before the targeted steady state is achieved.</p><p>Data from clinical studies suggest that the majority of patients can be successfully managed if tacrolimus blood trough levels are maintained below 20 ng/ml. It is necessary to consider the clinical condition of the patient when interpreting whole blood levels. In clinical practice, whole blood trough levels have generally been in the range 5 - 20 ng/ml in liver transplant recipients and 10 - 20 ng/ml in kidney and heart transplant patients in the early post-transplant period. During subsequent maintenance therapy, blood concentrations have generally been in the range of 5 - 15 ng/ml in liver, kidney and heart transplant recipients.</p><p><u>Special populations</u><br /><em>Hepatic&nbsp;impairment</em><br />Dose reduction may be necessary in patients with severe liver impairment in order to maintain the tacrolimus blood trough levels within the recommended target range.</p><p><em>Renal&nbsp;impairment</em><br />As the pharmacokinetics of tacrolimus are unaffected by renal function (see section 5.2), no dose adjustment is required. However, owing to the nephrotoxic potential of tacrolimus careful monitoring of renal function is recommended (including serial serum creatinine concentrations, calculation of creatinine clearance and monitoring of urine output).</p><p><em>Race</em><br />In comparison to Caucasians, black patients may require higher tacrolimus doses to achieve similar trough levels.</p><p><em>Gender</em><br />There is no evidence that male and female patients require different doses to achieve similar trough levels.</p><p><em>Older people</em><br />There is no evidence currently available to indicate that dosing should be adjusted in older people.</p><p><em>Paediatric population</em><br />The safety and efficacy of Advagraf in children under 18 years of age have not yet been established. Limited data are available but no recommendation on a posology can be made.</p><p><strong>Method of administration</strong><br />Advagraf is a once-a-day oral formulation of tacrolimus. It is recommended that the oral daily dose of Advagraf be administered once daily in the morning. Advagraf prolonged-release hard capsules should be taken immediately following removal from the blister. Patients should be advised not to swallow the desiccant. The capsules should be swallowed&nbsp;<strong><em>whole</em></strong>&nbsp;with fluid (preferably water). Advagraf should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption (see section 5.2). A forgotten morning dose should be taken as soon as possible on the same day. A double dose should not be taken on the next morning.</p><p>In patients unable to take oral medicinal products during the immediate post-transplant period, tacrolimus therapy can be initiated intravenously (see Summary of Product Characteristics for Prograf 5 mg/ml concentrate for solution for infusion) at a dose approximately 1/5<sup>th</sup>&nbsp;of the recommended oral dose for the corresponding indication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to tacrolimus, or to any of the excipients listed in section 6.1.

Hypersensitivity to other macrolides.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. This has led to serious adverse reactions, including graft rejection, or other adverse reactions which could be a consequence of either under- or over-exposure to tacrolimus. Patients should be maintained on a single formulation of tacrolimus with the corresponding daily dosing regimen; alterations in formulation or regimen should only take place under the close supervision of a transplant specialist (see sections 4.2 and 4.8).</p><p>Advagraf is not recommended for use in children below 18 years due to limited data on safety and/or efficacy.</p><p>For treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients clinical data are not yet available for the prolonged-release formulation Advagraf.</p><p>For prophylaxis of transplant rejection in adult heart allograft recipients clinical data are not yet available for Advagraf.</p><p>During the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations. If clinically relevant changes are seen, adjustments of the immunosuppressive regimen should be considered.</p><p><u>Substances with potential for interaction</u><br />Inhibitors or inducers of CYP3A4 should only be co-administered with tacrolimus after consulting a transplant specialist, due to the potential for drug interactions resulting in serious adverse reactions including rejection or toxicity (see section 4.5).</p><p><em>CYP3A4 inhibitors</em><br />Concomitant use with CYP3A4 inhibitors may increase tacrolimus blood levels, which could lead to serious adverse reactions, including nephrotoxicity, neurotoxicity and QT prolongation. It is recommended that concomitant use of strong CYP3A4 inhibitors (such as ritonavir, cobicistat, ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin or josamycin) with tacrolimus should be avoided. If unavoidable, tacrolimus blood levels should be monitored frequently,&nbsp;starting within the first few days of co-administration, under the supervision of a transplant specialist, to adjust the tacrolimus dose if appropriate in order to maintain similar tacrolimus exposure. Renal function, ECG including the QT interval, and the clinical condition of the patient should also be closely monitored.</p><p>Dose adjustment needs to be based upon the individual situation of each patient. An immediate dose reduction at the time of treatment initiation may be required (see section 4.5).</p><p>Similarly, discontinuation of CYP3A4 inhibitors may affect the rate of metabolism of tacrolimus, thereby leading to subtherapeutic blood levels of tacrolimus, and therefore requires close monitoring and supervision of a transplant specialist.</p><p><em>CYP3A4 inducers</em><br />Concomitant use with CYP3A4 inducers may decrease tacrolimus blood levels, potentially increasing the risk of transplant rejection. It is recommended that concomitant use of strong CYP3A4 inducers (such as rifampicin, phenytoin, carbamazepine) with tacrolimus should be avoided. If unavoidable, tacrolimus blood levels should be monitored frequently, starting within the first few days of co-administration, under the supervision of a transplant specialist, to adjust the tacrolimus dose if appropriate, in order to maintain similar tacrolimus exposure. Graft function should also be closely monitored (see section 4.5).</p><p>Similarly, discontinuation of CYP3A4 inducers may affect the rate of metabolism of tacrolimus, thereby leading to supratherapeutic blood levels of tacrolimus, and therefore requires close monitoring and supervision of a transplant specialist.</p><p><em>P-glycoprotein</em><br />Caution should be observed when co-administering tacrolimus with drugs that inhibit P-glycoprotein, as an increase in tacrolimus levels may occur<em>. </em>Tacrolimus whole blood levels and the clinical condition of the patient should be monitored closely. An adjustment of the tacrolimus dose may be required (see section 4.5).</p><p><em>Herbal preparations</em><br />Herbal preparations containing St. John&#39;s wort (Hypericum perforatum) or other herbal preparations should be avoided when taking Advagraf due to the risk of interactions that lead to either a decrease in blood concentrations of tacrolimus and reduced clinical effect of tacrolimus, or an increase in blood concentrations of tacrolimus and risk of tacrolimus toxicity (see section 4.5).</p><p><em>Other interactions</em><br />The combined administration of ciclosporin and tacrolimus should be avoided and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.5).</p><p>High potassium intake or potassium-sparing diuretics should be avoided (see section 4.5).</p><p>Certain combinations of tacrolimus with drugs known to have neurotoxic effects may increase the risk of these effects (see section 4.5).</p><p><em>Vaccination</em><br />Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided.</p><p><em>Nephrotoxicity</em><br />Tacrolimus can result in renal function impairment in post-transplant patients. Acute renal impairment without active intervention may progress to chronic renal impairment. Patients with impaired renal function should be monitored closely as the dosage of tacrolimus may need to be reduced. The risk for nephrotoxicity may increase when tacrolimus is concomitantly administered with drugs associated with nephrotoxicity (see section 4.5). Concurrent use of tacrolimus with drugs known to have nephrotoxic effects should be avoided. When co-administration cannot be avoided, tacrolimus trough blood level and renal function should be monitored closely and dosage reduction should be considered if nephrotoxicity occurs.</p><p><u>Gastrointestinal disorders</u><br />Gastrointestinal perforation has been reported in patients treated with tacrolimus. As gastrointestinal perforation is a medically important event that may lead to a life-threatening or serious condition, adequate treatments should be considered immediately after suspected symptoms or signs occur.</p><p>Since levels of tacrolimus in blood may significantly change during diarrhoea episodes, extra monitoring of tacrolimus concentrations is recommended during episodes of diarrhoea.</p><p><u>Cardiac disorders</u><br />Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies, have been observed in Prograf treated patients on rare occasions and may also occur with Advagraf. Most cases have been reversible, occurring with tacrolimus blood trough concentrations much higher than the recommended maximum levels. Other factors observed to increase the risk of these clinical conditions included pre-existing heart disease, corticosteroid usage, hypertension, renal or hepatic dysfunction, infections, fluid overload, and oedema. Accordingly, high-risk patients receiving substantial immunosuppression should be monitored, using such procedures as echocardiography or ECG pre- and post-transplant (e.g. initially at 3 months and then at 9 - 12 months). If abnormalities develop, dose reduction of Advagraf, or change of treatment to another immunosuppressive agent should be considered. Tacrolimus may prolong the QT interval and may cause&nbsp;Torsades de Pointes. Caution should be exercised in patients with risk factors for QT prolongation, including patients with a personal or family history of QT prolongation, congestive heart failure, bradyarrhythmias and electrolyte abnormalities. Caution should also be exercised in patients diagnosed or suspected to have Congenital Long QT Syndrome or acquired QT prolongation or patients on concomitant medications known to prolong the QT interval, induce electrolyte abnormalities or known to increase tacrolimus exposure (see section 4.5).</p><p><u>Lymphoproliferative disorders and malignancies</u><br />Patients treated with tacrolimus have been reported to develop Epstein-Barr-Virus (EBV)-associated lymphoproliferative disorders (see section 4.8). A combination of immunosuppressives such as antilymphocytic antibodies (e.g. basiliximab, daclizumab) given concomitantly increases the risk of EBV-associated lymphoproliferative disorders. EBV-Viral Capsid Antigen (VCA)-negative patients have been reported to have an increased risk of developing lymphoproliferative disorders. Therefore, in this patient group, EBV-VCA serology should be ascertained before starting treatment with Advagraf. During treatment, careful monitoring with EBV-PCR is recommended. Positive EBV-PCR may persist for months and is&nbsp;per se&nbsp;not indicative of lymphoproliferative disease or lymphoma.</p><p>As with other potent immunosuppressive compounds, the risk of secondary cancer is unknown (see section 4.8).</p><p>As with other immunosuppressive agents, owing to the potential risk of malignant skin changes, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p><u>Infections including opportunistic infections</u><br />Patients treated with immunosuppressants, including Advagraf are at increased risk for infections including opportunistic infections (bacterial, fungal, viral and protozoal) such as CMV infection, BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML). Patients are also at an increased risk of infections with viral hepatitis (for example, hepatitis B and C reactivation and de novo infection, as well as hepatitis E, which may become chronic). These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions including graft rejection that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating hepatic or renal function or neurological symptoms. Prevention and management should be in accordance with appropriate clinical guidance.</p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u><br />Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). If patients taking tacrolimus present with symptoms indicating PRES such as headache, altered mental status, seizures, and visual disturbances, a radiological procedure (e.g. MRI) should be performed. If PRES is diagnosed, adequate blood pressure and seizure control and immediate discontinuation of systemic tacrolimus is advised. Most patients completely recover after appropriate measures are taken.</p><p><u>Eye disorders</u><br />Eye disorders, sometimes progressing to loss of vision, have been reported in patients treated with tacrolimus. Some cases have reported resolution on switching to alternative immunosuppression. Patients should be advised to report changes in visual acuity, changes in colour vision, blurred vision, or visual field defect, and in such cases, prompt evaluation is recommended with referral to an ophthalmologist as appropriate.</p><p><u>Thrombotic microangiopathy (TMA) (including haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP))</u><br />The diagnosis of TMA, including thrombotic thrombocytopaenic purpura (TTP) and haemolytic uraemic syndrome (HUS), sometimes leading to renal failure or a fatal outcome, should be considered in patients presenting with haemolytic anaemia, thrombocytopenia, fatigue, fluctuating neurological manifestation, renal impairment, and fever. If TMA is diagnosed, prompt treatment is required, and discontinuation of tacrolimus should be considered at the discretion of the treating physician.</p><p>The concomitant administration of tacrolimus with a mammalian target of rapamycin (mTOR) inhibitor (e.g., sirolimus, everolimus) may increase the risk of thrombotic microangiopathy (including haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura).</p><p><u>Pure Red Cell Aplasia</u><br />Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. All patients reported risk factors for PRCA such as parvovirus B19 infection, underlying disease or concomitant medications associated with PRCA.</p><p><u>Special populations</u><br />There is limited experience in non-Caucasian patients and patients at elevated immunological risk (e.g. retransplantation, evidence of panel reactive antibodies, PRA).</p><p>Dose reduction may be necessary in patients with severe liver impairment (see section 4.2).</p><p><u>Excipients</u><br />Advagraf contains lactose monohydrate. Each prolonged-release hard capsule of Advagraf 0.5 mg Prolonged-release Hard Capsules contains 53.64 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Advagraf<strong> </strong>contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per prolonged-release hard capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>The printing ink used on Advagraf prolonged-release hard capsules<strong> </strong>contains lecithin (soya). Each prolonged-release hard capsule of Advagraf 0.5 mg Prolonged-release Hard Capsules contains 0.0009 mg lecithin (soya). If you are allergic to peanut or soya, talk to your doctor to determine whether you should use this medicine.<strong>&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Metabolic interactions</em><br />Systemically available tacrolimus is metabolised by hepatic CYP3A4. There is also evidence of gastrointestinal metabolism by CYP3A4 in the intestinal wall. Concomitant use of medicinal products or herbal remedies known to inhibit or induce CYP3A4 may affect the metabolism of tacrolimus and thereby increase or decrease tacrolimus blood levels.</p><p>Similarly, discontinuation of such products or herbal remedies may affect the rate of metabolism of tacrolimus and thereby the blood levels of tacrolimus.</p><p>Pharmacokinetics studies have indicated that the increase in tacrolimus blood levels when co-administered with inhibitors of CYP3A4 is mainly a result of increase in oral bioavailability of tacrolimus owing to the inhibition of gastrointestinal metabolism. Effect on hepatic clearance is less pronounced.</p><p>It is recommended strongly to closely monitor tacrolimus blood levels under supervision of a transplant specialist, as well as, monitor for graft function, QT prolongation (with ECG), renal function and other side effects including neurotoxicity, whenever substances which have the potential to alter CYP3A4 metabolism are used concomitantly, and to adjust or interrupt the tacrolimus dose if appropriate in order to maintain similar tacrolimus exposure (see sections 4.2 and 4.4). Similarly, patients should be closely monitored when using tacrolimus concomitantly with multiple substances that affect CYP3A4 as the effects on tacrolimus exposure may be enhanced or counteracted.</p><p>Medicinal products which have effects on tacrolimus are listed in the table below. The examples of drug-drug interactions are not intended to be inclusive or comprehensive and therefore the label of each drug that is co-administered with tacrolimus should be consulted for information related to the route of metabolism, interaction pathways, potential risks, and specific actions to be taken with regards to co-administration.</p><p>Medicinal products which have effects on tacrolimus</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Drug/Substance Class or Name</p></td><td style="vertical-align:top"><p>Drug interaction effect</p></td><td style="vertical-align:top"><p>Recommendations concerning co-administration</p></td></tr><tr><td style="vertical-align:top"><p>Grapefruit or grapefruit juice</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation)&nbsp;<em>[see section 4.4].</em></p></td><td style="vertical-align:top"><p>Avoid grapefruit or grapefruit juice.</p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations. In addition, synergistic/additive nephrotoxic effects can occur.</p></td><td style="vertical-align:top"><p>The simultaneous use of ciclosporin and tacrolimus should be avoided&nbsp;<em>[see section 4.4].</em></p></td></tr><tr><td style="vertical-align:top"><p>Products known to have nephrotoxic or neurotoxic effects:</p><p>aminoglycosides, gyrase inhibitors, vancomycin, sulfamethoxazole + trimethoprim, NSAIDs, ganciclovir, acyclovir, amphotericin B, ibuprofen, cidofovir, foscarnet</p></td><td style="vertical-align:top"><p>May enhance nephrotoxic or neurotoxic effects of tacrolimus.</p></td><td style="vertical-align:top"><p>Concurrent use of tacrolimus with drugs known to have nephrotoxic effects should be avoided. When co-administration cannot be avoided, monitor renal function and other side effects and adjust tacrolimus dose if needed.</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP3A4 inhibitors:</p><p>antifungal agents (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), the macrolide antibiotics (e.g., telithromycin, troleandomycin, clarithromycin, josamycin), HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir), HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), nefazodone, the pharmacokinetic enhancer cobicistat, and the kinase inhibitors idelalisib, ceritinib.</p><p>Strong interactions have also been observed with the macrolide antibiotic erythromycin.</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., nephrotoxicity, neurotoxicity, QT prolongation) which requires close monitoring&nbsp;<em>[see section 4.4].</em></p><p>Rapid and sharp increases in tacrolimus levels may occur, as early as within 1-3 days after co-administration, despite immediate reduction of tacrolimus dose. Overall tacrolimus exposure may increase &gt; 5 fold. When ritonavir combinations are co-administered, tacrolimus exposure may increase &gt; 50 fold. Nearly all patients may require a reduction in tacrolimus dose and temporary interruption of tacrolimus may also be necessary.</p><p>The effect on tacrolimus blood concentrations may remain for several days after co-administration is completed.</p></td><td style="vertical-align:top"><p>It is recommended that concomitant use should be avoided. If co-administration of a strong CYP3A4 inhibitor is unavoidable, consider omitting the dose of tacrolimus the day the strong CYP3A4 inhibitor is initiated. Reinitiate tacrolimus the next day at a reduced dose based on tacrolimus blood concentrations. Changes in both tacrolimus dose and/or dosing frequency should be individualized and adjusted as needed based on tacrolimus trough concentrations, which should be assessed at initiation, monitored frequently throughout (starting within the first few days) and re-evaluated on and after completion of the CYP3A4 inhibitor. Upon completion, appropriate dose and dosing frequency of tacrolimus should be guided by tacrolimus blood concentrations. Monitor renal function, ECG for QT prolongation, and other side effects closely.</p></td></tr><tr><td style="vertical-align:top"><p>Moderate or weak CYP3A4 inhibitors:</p><p>antifungal agents (e.g., fluconazole, isavuconazole, clotrimazole, miconazole), the macrolide antibiotics (e.g., azithromycin), calcium channel blockers (e.g., nifedipine, nicardipine, diltiazem, verapamil), amiodarone, danazol, ethinylestradiol, lansoprazole, omeprazole, the HCV antivirals elbasvir/grazoprevir and glecaprevir/pibrentasvir, the CMV antiviral letermovir, and the tyrosine kinase inhibitors nilotinib, crizotinib and imatinib and (Chinese) herbal remedies containing extracts of&nbsp;<em>Schisandra sphenanthera</em></p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation)&nbsp;<em>[see section 4.4]</em>. A rapid increase in tacrolimus level may occur.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations frequently, starting within the first few days of co-administration. Reduce tacrolimus dose if needed&nbsp;<em>[see section 4.2].</em>&nbsp;Monitor renal function, ECG for QT prolongation, and other side effects closely.</p></td></tr><tr><td style="vertical-align:top"><p><em>In vitro</em>&nbsp;the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen.</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation)&nbsp;<em>[see section 4.4].</em></p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed&nbsp;<em>[see section 4.2].</em></p><p>Monitor renal function, ECG for QT prolongation, and other side effects closely.</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP3A4 inducers:</p><p>rifampicin, phenytoin carbamazepine, apalutamide, enzalutamide, mitotane, or St. John&#39;s wort (<em>Hypericum perforatum</em>)</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection&nbsp;<em>[see section 4.4].</em></p><p>Maximal effect on tacrolimus blood concentrations may be achieved 1-2 weeks after co-administration. The effect may remain 1-2 weeks after completion of the treatment.</p></td><td style="vertical-align:top"><p>It is recommended that concomitant use should be avoided. If unavoidable, patients may require an increase in tacrolimus dose. Changes in tacrolimus dose should be individualized and adjusted as needed based on tacrolimus trough concentrations, which should be assessed at initiation, monitored frequently throughout (starting within the first few days) and re-evaluated on and after completion of the CYP3A4 inducer. After use of the CYP3A4 inducer has ended, tacrolimus dose may need to be adjusted gradually. Monitor graft function closely.</p></td></tr><tr><td style="vertical-align:top"><p>Moderate CYP3A4 inducers:</p><p>metamizole, phenobarbital, isoniazid, rifabutin, efavirenz, etravirine, nevirapine; weak CYP3A4 inducers: flucloxacillin</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection&nbsp;<em>[see section 4.4].</em></p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and increase tacrolimus dose if needed&nbsp;<em>[see section 4.2].</em>&nbsp;Monitor graft function closely.</p></td></tr><tr><td style="vertical-align:top"><p>Caspofungin</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection. Mechanism of interaction has not been confirmed.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and increase tacrolimus dose if needed [see section 4.2]. Monitor graft function closely.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cannabidiol (P-gp inhibitor)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>There have been reports of increased tacrolimus blood levels during concomitant use of tacrolimus with cannabidiol. This may be due to inhibition of intestinal P-glycoprotein, leading to increased bioavailability of tacrolimus.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tacrolimus and cannabidiol should be co-administered with caution, closely monitoring for side effects. Monitor tacrolimus whole blood trough concentrations and adjust the tacrolimus dose if needed [see sections 4.2 and 4.4].</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Products known to have high affinity for plasma proteins, e.g.: NSAIDs, oral anticoagulants, oral antidiabetics</p></td><td style="vertical-align:top"><p>Tacrolimus is extensively bound to plasma proteins. Possible interactions with other active substances known to have high affinity for plasma proteins should be considered.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed&nbsp;<em>[see section 4.2].</em></p></td></tr><tr><td style="vertical-align:top"><p>Prokinetic agents: metoclopramide, cimetidine and magnesium-aluminium-hydroxide</p></td><td style="vertical-align:top"><p>May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation).</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and reduce tacrolimus dose if needed&nbsp;<em>[see section 4.2].</em>&nbsp;Monitor closely for renal function, for QT prolongation with ECG, and for other side effects.</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance doses of corticosteroids</p></td><td style="vertical-align:top"><p>May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection&nbsp;<em>[see section 4.4].</em></p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and increase tacrolimus dose if needed&nbsp;<em>[see section 4.2]</em>. Monitor graft function closely.</p></td></tr><tr><td style="vertical-align:top"><p>High dose prednisolone or methylprednisolone</p></td><td style="vertical-align:top"><p>May have impact on tacrolimus blood levels (increase or decrease) when administered for the treatment of acute rejection.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed.</p></td></tr><tr><td style="vertical-align:top"><p>Direct-acting antiviral (DAA) therapy</p></td><td style="vertical-align:top"><p>May have impact on the pharmacokinetics of tacrolimus by changes in liver function during DAA therapy, related to clearance of hepatitis virus. A decrease in tacrolimus blood levels may occur.</p><p>However, the CYP3A4 inhibiting potential of some DAAs may counteract that effect or lead to increased tacrolimus blood levels.</p></td><td style="vertical-align:top"><p>Monitor tacrolimus whole blood trough concentrations and adjust tacrolimus dose if needed to ensure continued efficacy and safety.</p></td></tr></tbody></table><p>Concomitant administration of tacrolimus with a mammalian target of rapamycin (mTOR) inhibitor (e.g., sirolimus, everolimus) may increase the risk of thrombotic microangiopathy (including haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura) (see section 4.4).</p><p>As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or spironolactone) should be avoided (see section 4.4). Care should be taken when tacrolimus is co-administered with other agents that increase serum potassium, such as trimethoprim and cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. Close monitoring of serum potassium is recommended.</p><p><u>Effect of tacrolimus on the metabolism of other medicinal products</u><br />Tacrolimus is a known CYP3A4 inhibitor; thus concomitant use of tacrolimus with medicinal products known to be metabolised by CYP3A4 may affect the metabolism of such medicinal products.</p><p>The half-life of ciclosporin is prolonged when tacrolimus is given concomitantly. In addition, synergistic/additive nephrotoxic effects can occur. For these reasons, the combined administration of ciclosporin and tacrolimus is not recommended and care should be taken when administering tacrolimus to patients who have previously received ciclosporin (see sections 4.2 and 4.4).</p><p>Tacrolimus has been shown to increase the blood level of phenytoin.</p><p>As tacrolimus may reduce the clearance of steroid-based contraceptives leading to increased hormone exposure, particular care should be exercised when deciding upon contraceptive measures.</p><p>Limited knowledge of interactions between tacrolimus and statins is available. Clinical data suggest that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus.</p><p>Animal data have shown that tacrolimus could potentially decrease the clearance and increase the halflife of pentobarbital and antipyrine.</p><p>Mycophenolic acid. Caution should be exercised when switching combination therapy from ciclosporin, which interferes with enterohepatic recirculation of mycophenolic acid, to tacrolimus, which is devoid of this effect, as this might result in changes of mycophenolic acid exposure. Drugs which interfere with mycophenolic acid&#39;s enterohepatic cycle have potential to reduce the plasma level and efficacy of mycophenolic acid. Therapeutic drug monitoring of mycophenolic acid may be appropriate when switching from ciclosporin to tacrolimus or vice versa.</p><p>Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />Human data show that tacrolimus crosses the placenta. Limited data from organ transplant recipients show no evidence of an increased risk of adverse reactions on the course and outcome of pregnancy under tacrolimus treatment compared with other immunosuppressive medicinal products. However, cases of spontaneous abortion have been reported. To date, no other relevant epidemiological data are available. Tacrolimus treatment can be considered in pregnant women, when there is no safer alternative and when the perceived benefit justifies the potential risk to the foetus. In case of&nbsp;<em>in utero</em>&nbsp;exposure, monitoring of the newborn for the potential adverse events of tacrolimus is recommended (in particular effects on the kidneys). There is a risk for premature delivery (&lt;37 week) (incidence of 66 of 123 births, i.e. 53.7%; however, data showed that the majority of the newborns had normal birth weight for their gestational age) as well as for hyperkalaemia in the newborn (incidence 8 of 111 neonates, i.e. 7.2 %) which, however normalises spontaneously.</p><p>In rats and rabbits, tacrolimus caused embryofoetal toxicity at doses which demonstrated maternal toxicity (see section 5.3).</p><p><u>Breast-feeding</u><br />Human data demonstrate that tacrolimus is excreted in breast milk. As detrimental effects on the newborn cannot be excluded, women should not breast-feed whilst receiving Advagraf.</p><p><u>Fertility</u><br />A negative effect of tacrolimus on male fertility in the form of reduced sperm counts and motility was observed in rats (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus may cause visual and neurological disturbances. This effect may be enhanced if tacrolimus is administered in association with alcohol.</p><p>No studies on the effects of tacrolimus (Advagraf) on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reaction profile associated with immunosuppressive agents is often difficult to establish owing to the underlying disease and the concurrent use of multiple medicinal products.</p><p>The most commonly reported adverse reactions (occurring in &gt; 10% of patients) are tremor, renal impairment, hyperglycaemic conditions, diabetes mellitus, hyperkalaemia, infections, hypertension and insomnia.</p><p>The frequency of adverse reactions is defined as follows: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><u>Infections and infestations</u><br />As is well known for other potent immunosuppressive agents, patients receiving tacrolimus are frequently at increased risk for infections (viral, bacterial, fungal, protozoal). The course of pre-existing infections may be aggravated. Both generalised and localised infections can occur.</p><p>Cases of CMV infection, BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Advagraf.</p><p><u>Neoplasms benign, malignant and unspecified (incl. cysts and polyps)</u><br />Patients receiving immunosuppressive therapy are at increased risk of developing malignancies. Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Anaemia, thrombocytopenia, leukopenia, red blood cell analyses abnormal, leukocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Coagulopathies, pancytopenia, neutropenia, coagulation and bleeding analyses, abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Thrombotic thrombocytopenic purpura, hypoprothrombinaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Pure red cell aplasia, agranulocytosis, haemolytic anaemia, febrile neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Immune system disorders</u></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Allergic and anaphylactoid reactions have been observed in patients receiving tacrolimus (see section 4.4).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Endocrine disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hirsutism</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Metabolism and nutrition disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Diabetes mellitus, hyperglycaemic conditions, hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcaemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphataemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dehydration, hypoglycaemia, hypoproteinaemia, hyperphosphataemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Psychiatric disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Confusion and disorientation, depression, anxiety symptoms, hallucination, mental disorders, depressed mood, mood disorders and disturbances, nightmare</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Psychotic disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Nervous system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache, tremor</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nervous system disorders seizures, disturbances in consciousness, peripheral neuropathies, dizziness, paraesthesias and dysaesthesias, writing impaired</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Encephalopathy, central nervous system haemorrhages and cerebrovascular accidents, coma, speech and language abnormalities, paralysis and paresis, amnesia</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hypertonia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p><p>Not known</p></td><td style="vertical-align:top"><p>Myasthenia</p><p>Posterior reversible encephalopathy syndrome (PRES)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Eye disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Eye disorders, vision blurred, photophobia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Cataract</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Blindness</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Optic neuropathy</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Ear and labyrinth disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypoacusis</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Deafness neurosensory</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hearing impaired</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Cardiac disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Ischaemic coronary artery disorders, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Heart failures, ventricular arrhythmias and cardiac arrest, supraventricular arrhythmias, cardiomyopathies, ventricular hypertrophy, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Pericardial effusion</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Torsades de Pointes</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Venous thrombosis deep limb, shock, infarction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Respiratory, thoracic and mediastinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Parenchymal lung disorders, dyspnoea, pleural effusion, cough, pharyngitis, nasal congestion and inflammations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Respiratory failures, respiratory tract disorders, asthma</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Gastrointestinal signs and symptoms, vomiting, gastrointestinal and abdominal pains, gastrointestinal inflammatory conditions, gastrointestinal haemorrhages, gastrointestinal ulceration and perforation, ascites, stomatitis and ulceration, constipation, dyspeptic signs and symptoms, flatulence, bloating and distension, loose stools</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Acute and chronic pancreatitis, ileus paralytic, gastrooesophageal reflux disease, impaired gastric emptying</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Pancreatic pseudocyst, subileus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Venoocclusive liver disease, hepatitic artery thrombosis</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hepatic failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Rash, pruritus, alopecias, acne, sweating increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dermatitis, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis (Lyell&#39;s syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Stevens Johnson syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Musculoskeletal and connective tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Arthralgia, back pain, muscle spasms, pain in extremity</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Joint disorders</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Mobility decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Renal impairment</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Renal failure, renal failure acute, nephropathy toxic, renal tubular necrosis, urinary abnormalities, oliguria, bladder and urethral symptoms</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Haemolytic uraemic syndrome, anuria</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Nephropathy, cystitis haemorrhagic</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Reproductive system and breast disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dysmenorrhoea and uterine bleeding</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Febrile disorders, pain and discomfort, asthenic conditions, oedema, body temperature perception disturbed</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Influenza like illness, feeling jittery, feeling abnormal, multi-organ failure, chest pressure sensation, temperature intolerance</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Fall, ulcer, chest tightness, thirst</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Fat tissue increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Investigations</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Liver function tests abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased, weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Amylase increased, ECG investigations abnormal, heart rate and pulse investigations abnormal, weight decreased, blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Echocardiogram abnormal, electrocardiogram QT prolonged</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><u>Injury, poisoning and procedural complications</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Primary graft dysfunction</p></td></tr></tbody></table><p>&nbsp;</p><p>Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. A number of associated cases of transplant rejection have been reported (frequency cannot be estimated from available data).</p><p><u>Description of selected adverse reactions</u><br />Pain in extremity has been described in a number of published case reports as part of Calcineurin-Inhibitor Induced Pain Syndrome (CIPS). This typically presents as a bilateral and symmetrical, severe, ascending pain in the lower extremities and may be associated with supra-therapeutic levels of tacrolimus. The syndrome may respond to tacrolimus dose reduction. In some cases, it was necessary to switch to alternative immunosuppression.</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with overdose is limited. Several cases of accidental overdose have been reported with tacrolimus; symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy and increases in blood urea nitrogen, serum creatinine and alanine aminotransferase levels.</p><p>No specific antidote to tacrolimus therapy is available. If overdose occurs, general supportive measures and symptomatic treatment should be conducted.</p><p>Based on its high molecular weight, poor aqueous solubility, and extensive erythrocyte and plasma protein binding, it is anticipated that tacrolimus will not be dialysable. In isolated patients with very high plasma levels, haemofiltration or -diafiltration have been effective in reducing toxic concentrations. In cases of oral intoxication, gastric lavage and/or the use of adsorbents (such as activated charcoal) may be helpful, if used shortly after intake.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, calcineurin inhibitors, ATC code: L04AD02.</p><p><u>Mechanism of action</u><br />At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP12) which is responsible for the intracellular accumulation of the compound. The FKBP12-tacrolimus complex specifically and competitively binds to and inhibits calcineurin, leading to a calcium-dependent inhibition of T-cell signal transduction pathways, thereby preventing transcription of a discrete set of cytokine genes.</p><p>Tacrolimus is a highly potent immunosuppressive agent and has proven activity in both&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;experiments.</p><p>In particular, tacrolimus inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and &gamma;-interferon) and the expression of the interleukin-2 receptor.</p><p><u>Results from clinical trials performed with once-daily tacrolimus Advagraf</u><br /><em>Liver transplantation</em><br />The efficacy and safety of Advagraf and Prograf, both in combination with corticosteroids, was compared in 471&nbsp;<em>de novo</em>&nbsp;liver transplant recipients. The event rate of biopsy confirmed acute rejection within the first 24 weeks after transplantation was 32.6% in the Advagraf group (N=237) and 29.3% in the Prograf group (N=234). The treatment difference (Advagraf &ndash; Prograf) was 3.3% (95% confidence interval [-5.7%, 12.3%]).The 12‑month patient survival rates were 89.2% for Advagraf and 90.8% for Prograf; in the Advagraf arm 25 patients died (14 female, 11 male) and in the Prograf arm 24 patients died (5 female, 19 male). 12-month graft survival was 85.3% for Advagraf and 85.6% for Prograf.</p><p><em>Kidney transplantation</em><br />The efficacy and safety of Advagraf and Prograf, both in combination with mycophenolate mofetil (MMF) and corticosteroids, was compared in 667&nbsp;<em>de novo</em>&nbsp;kidney transplant recipients. The event rate for biopsy-confirmed acute rejection within the first 24 weeks after transplantation was 18.6% in the Advagraf group (N=331) and 14.9% in the Prograf group (N=336). The treatment difference (Advagraf-Prograf) was 3.8% (95% confidence interval [-2.1%, 9.6%]). The 12‑month patient survival rates were 96.9% for Advagraf and 97.5% for Prograf; in the Advagraf arm 10 patients died (3 female, 7 male) and in the Prograf arm 8 patients died (3 female, 5 male). 12-month graft survival was 91.5% for Advagraf and 92.8% for Prograf.</p><p>The efficacy and safety of Prograf, ciclosporin and Advagraf, all in combination with basiliximab antibody induction, MMF and corticosteroids, was compared in 638&nbsp;<em>de novo</em>&nbsp;kidney transplant recipients. The incidence of efficacy failure at 12 months (defined as death, graft loss, biopsy-confirmed acute rejection, or lost to follow-up) was 14.0% in the Advagraf group (N=214), 15.1% in the Prograf group (N=212) and 17.0% in the ciclosporin group (N=212). The treatment difference was -3.0% (Advagraf-ciclosporin) (95.2% confidence interval [-9.9%, 4.0%]) for Advagraf vs. ciclosporin and -1.9% (Prograf-ciclosporin) (95.2% confidence interval [-8.9%, 5.2%]) for Prograf vs. ciclosporin. The 12-month patient survival rates were 98.6% for Advagraf, 95.7% for Prograf and 97.6% for ciclosporin; in the Advagraf arm 3 patients died (all male), in the Prograf arm 10 patients died (3 female, 7 male) and in the ciclosporin arm 6 patients died (3 female, 3 male). 12-month graft survival was 96.7% for Advagraf, 92.9% for Prograf and 95.7% for ciclosporin.</p><p><u>Clinical efficacy and safety of Prograf capsules bid in primary organ transplantation</u><br />In prospective studies oral Prograf was investigated as primary immunosuppressant in approximately 175 patients following lung, 475 patients following pancreas and 630 patients following intestinal transplantation. Overall, the safety profile of oral Prograf in these published studies appeared to be similar to what was reported in the large studies, where Prograf was used as primary treatment in liver, kidney and heart transplantation. Efficacy results of the largest studies in each indication are summarised below.</p><p><em>Lung transplantation</em><br />The interim analysis of a recent multicentre study using oral Prograf discussed 110 patients who underwent 1:1 randomisation to either tacrolimus or ciclosporin.</p><p>Tacrolimus was started as continuous intravenous infusion at a dose of 0.01 to 0.03 mg/kg/day and oral tacrolimus was administered at a dose of 0.05 to 0.3 mg/kg/day. A lower incidence of acute rejection episodes for tacrolimus- versus ciclosporin-treated patients (11.5% versus 22.6%) and a lower incidence of chronic rejection, the bronchiolitis obliterans syndrome (2.86% versus 8.57%), was reported within the first year after transplantation. The 1-year patient survival rate was 80.8% in the tacrolimus and 83% in the ciclosporin group.</p><p>Another randomised study included 66 patients on tacrolimus versus 67 patients on ciclosporin. Tacrolimus was started as continuous intravenous infusion at a dose of 0.025 mg/kg/day and oral tacrolimus was administered at a dose of 0.15 mg/kg/day with subsequent dose adjustments to target trough levels of 10 to 20 ng/ml. The 1-year patient survival was 83% in the tacrolimus and 71% in the ciclosporin group, the 2-year survival rates were 76% and 66%, respectively. Acute rejection episodes per 100 patient-days were numerically fewer in the tacrolimus (0.85 episodes) than in the ciclosporin group (1.09 episodes). Obliterative bronchiolitis developed in 21.7% of patients in the tacrolimus group compared with 38.0% of patients in the ciclosporin group (p = 0.025). Significantly more ciclosporin-treated patients (n = 13) required a switch to tacrolimus than tacrolimus-treated patients to ciclosporin (n = 2) (p = 0.02) (Keenan et al., Ann Thoracic Surg 1995; 60:580).</p><p>In an additional two-centre study, 26 patients were randomised to the tacrolimus versus 24 patients to the ciclosporin group. Tacrolimus was started as continuous intravenous infusion at a dose of 0.05 mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3 mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 ng/ml. The 1-year survival rates were 73.1% in the tacrolimus versus 79.2% in the ciclosporin group. Freedom from acute rejection was higher in the tacrolimus group at 6 months (57.7% versus 45.8%) and at 1 year after lung transplantation (50% versus 33.3%).</p><p>The three studies demonstrated similar survival rates. The incidences of acute rejection were numerically lower with tacrolimus in all three studies and one of the studies reported a significantly lower incidence of bronchiolitis obliterans syndrome with tacrolimus.</p><p><em>Pancreas transplantation</em><br />A multicentre study using oral Prograf included 205 patients undergoing simultaneous pancreas-kidney transplantation who were randomised to tacrolimus (n = 103) or to ciclosporin (n = 102). The initial oral per protocol dose of tacrolimus was 0.2 mg/kg/day with subsequent dose adjustments to target trough levels of 8 to 15 ng/ml by Day 5 and 5 to 10 ng/ml after Month 6. Pancreas survival at 1 year was significantly superior with tacrolimus: 91.3% versus 74.5% with ciclosporin (p &lt; 0.0005), whereas renal graft survival was similar in both groups. In total 34 patients switched treatment from ciclosporin to tacrolimus, whereas only 6 tacrolimus patients required alternative therapy.</p><p><em>Intestinal transplantation</em><br />Published clinical experience from a single centre on the use of oral Prograf for primary treatment following intestinal transplantation showed that the actuarial survival rate of 155 patients (65 intestine alone, 75 liver and intestine, and 25 multivisceral) receiving tacrolimus and prednisone was 75% at 1 year, 54% at 5 years, and 42% at 10 years. In the early years the initial oral dose of tacrolimus was 0.3 mg/kg/day. Results continuously improved with increasing experience over the course of 11 years. A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />In man tacrolimus has been shown to be able to be absorbed throughout the gastrointestinal tract. Available tacrolimus is generally rapidly absorbed. Advagraf is a prolonged-release formulation of tacrolimus resulting in an extended oral absorption profile with an average time to maximum blood concentration (C<sub>max</sub>) of approximately 2 hours (t<sub>max</sub>).</p><p>Absorption is variable and the mean oral bioavailability of tacrolimus (investigated with the Prograf formulation) is in the range of 20% - 25% (individual range in adult patients 6% - 43%). The oral bioavailability of Advagraf was reduced when it was administered after a meal. Both the rate and extent of absorption of Advagraf were reduced when administered with food.</p><p>Bile flow does not influence the absorption of tacrolimus and therefore treatment with Advagraf may commence orally.</p><p>A strong correlation exists between AUC and whole blood trough levels at steady-state for Advagraf. Monitoring of whole blood trough levels therefore provides a good estimate of systemic exposure.</p><p><u>Distribution</u><br />In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic.</p><p>In the systemic circulation, tacrolimus binds strongly to erythrocytes resulting in an approximate 20:1 distribution ratio of whole blood/plasma concentrations. In plasma, tacrolimus is highly bound (&gt; 98.8%) to plasma proteins, mainly to serum albumin and &alpha;-1-acid glycoprotein.</p><p>Tacrolimus is extensively distributed in the body. The steady-state volume of distribution based on plasma concentrations is approximately 1300 l (healthy subjects). Corresponding data based on whole blood averaged 47.6 l.</p><p><u>Metabolism</u><br />Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4 (CYP3A4) and the cytochrome P450-3A5 (CYP3A5). Tacrolimus is also considerably metabolised in the intestinal wall. There are several metabolites identified. Only one of these has been shown&nbsp;<em>in vitro</em>&nbsp;to have immunosuppressive activity similar to that of tacrolimus. The other metabolites have only weak or no immunosuppressive activity. In systemic circulation only one of the inactive metabolites is present at low concentrations. Therefore, metabolites do not contribute to the pharmacological activity of tacrolimus.</p><p><u>Excretion</u><br />Tacrolimus is a low-clearance substance. In healthy subjects, the average total body clearance estimated from whole blood concentrations was 2.25 l/h. In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed. Factors such as low haematocrit and protein levels, which result in an increase in the unbound fraction of tacrolimus, or corticosteroid-induced increased metabolism, are considered to be responsible for the higher clearance rates observed following transplantation.</p><p>The half-life of tacrolimus is long and variable. In healthy subjects, the mean half-life in whole blood is approximately 43 hours.</p><p>Following intravenous and oral administration of&nbsp;<sup>14</sup>C-labelled tacrolimus, most of the radioactivity was eliminated in the faeces. Approximately 2% of the radioactivity was eliminated in the urine. Less than 1% of unchanged tacrolimus was detected in the urine and faeces, indicating that tacrolimus is almost completely metabolised prior to elimination: bile being the principal route of elimination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The kidneys and the pancreas were the primary organs affected in toxicity studies performed in rats and baboons. In rats, tacrolimus caused toxic effects to the nervous system and the eyes. Reversible cardiotoxic effects were observed in rabbits following intravenous administration of tacrolimus.</p><p>When tacrolimus is administered intravenously as rapid infusion/bolus injection at a dose of 0.1 to 1.0 mg/kg, QTc prolongation has been observed in some animal species. Peak blood concentrations achieved with these doses were above 150 ng/mL which is more than 6-fold higher than mean peak concentrations observed with Advagraf in clinical transplantation.</p><p>Embryofoetal toxicity was observed in rats and rabbits and was limited to doses that caused significant toxicity in maternal animals. In rats, female reproductive function including birth was impaired at toxic doses and the offspring showed reduced birth weights, viability and growth.</p><p>A negative effect of tacrolimus on male fertility in the form of reduced sperm counts and motility was observed in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content:</u><br />-&nbsp;&nbsp; Hypromellose<br />-&nbsp;&nbsp; Ethylcellulose<br />-&nbsp;&nbsp; Lactose monohydrate<br />-&nbsp;&nbsp; Magnesium stearate.</p><p><u>Capsule shell:</u><br />-&nbsp;&nbsp; Titanium dioxide<br />-&nbsp;&nbsp; Yellow iron oxide<br />-&nbsp;&nbsp; Red iron oxide<br />-&nbsp;&nbsp; Gelatin<br />-&nbsp;&nbsp; Sodium lauryl sulfate.</p><p><u>Printing ink:</u>&nbsp;<br />-&nbsp;&nbsp; Shellac<br />-&nbsp;&nbsp; Lecithin (soya)<br />-&nbsp;&nbsp; Simethicone<br />-&nbsp;&nbsp; Ferric oxide red<br />-&nbsp;&nbsp; Hydroxypropyl cellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tacrolimus is not compatible with PVC (polyvinylchloride). Tubing, syringes and other equipment used to prepare a suspension of Advagraf prolonged-release hard capsule contents must not contain PVC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
After opening the aluminum wrapper: 1 year.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p><p>Use all the prolonged-release hard capsules within 1 year of opening the aluminum wrapping.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC-aluminum blisters wrapped in an aluminum pouch with a desiccant.</p><p>Pack size: 100 Prolonged-release Hard Capsules (2 aluminum pouches, each aluminum pouch contains 50 Prolonged-release Hard Capsules).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09 September 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>